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ABSTRACT 
ADAM MICHAEL AZMAN: Spiroketals as Natural Product Mimics and Progress toward 
the Total Synthesis of Milbemcyin β14 
 
(Under the direction of Michael T. Crimmins, Ph.D.) 
 
A modular synthesis of spiroketals is herein reported.  The synthesis allows for 
stereocontroled introduction of substituents in strategic positions about the pyran rings.  The 
modular approach provides quick synthetic access to stereodefined fragments which can be 
coupled in various combinations to provide the carbon backbone of a library of spiroketals.  
Goals of the project include predictable and specified vector relationships between 
functionalized substituents about the spiroketal scaffold.  Spiroketals were chosen as 
scaffolds due to the three dimensional rigidity resulting from the energetic stabilization called 
the anomeric effect.  The synthetic route to spiroketals is adapted to the synthesis of the 
spiroketal fragment of the natural product milbemycin β14.  Progress toward the total 
synthesis is reported. 
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CHAPTER 1 
1.INTRODUCTION 
A. Background 
(i) Natural Products in Medicinal Chemistry 
Natural products are arguably the most important source of inspiration for targets of 
pharmaceutical compounds used in medicine.  For decades, the compounds isolated from 
nature have been a source of unique and interesting chemical structures, and many have 
intriguing biological activity for the treatment of disease.1–3  As a result, compounds isolated 
from Nature routinely impact drug discovery and appear, in whole or in inspiration, in the 
new chemical entities filed with the U.S. Food and Drug Administration.3  For example, the 
class of antibiotics has benefited from the discovery of the penicillins and erythromycins, and 
the class of chemotherapy drugs has benefited from the discovery of taxol and the vinca 
alkaloids (Figure 1.1).  As of 2002, 75% of antibiotics and 60% of anticancer agents have 
been derived from natural sources.3 
 2 
 
 
Figure 1.1: Medicinally Important Natural Products 
A popular subclass of isolated natural products is the polyketides, natural products 
characterized by repeating polypropionate and polyacetate units.4,5  While naturally occurring 
polyketides often have potent biological activity themselves, synthesizing derivatives of 
these natural products with minor structural changes is a popular synthetic technique aimed 
at identifying molecules with a better medicinal profile.  Goals of this process include 
improved biological activity, better physical characteristics, or simplified structures which 
make synthesis more amenable to large scale efforts. 
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(ii) Diversity-Oriented Synthesis 
One strategy aimed at rapid preparation of natural product derivatives is diversity-
oriented synthesis.  Utilizing commercially available starting materials, rigid and highly 
functionalized scaffolds with high levels of structural complexity are prepared using 
powerful chemical transformations.6–13  Diversity-oriented synthesis can focus on the 
preparation of small libraries of potential medicinal compounds based on privileged 
substructures known to be biologically active.  Alternatively, diversity-oriented synthesis can 
focus on the preparation of diverse structural scaffolds with a wide variety of functional 
groups with the goal of creating “natural product-like” molecules.  These molecules possess 
potential pharmacophores which may not necessarily be naturally occurring, but have the 
potential to impart potent biological activity.  These compounds are herein called “natural 
product mimics” (NPMs) and potentially allow for the maximum possible chemical 
diversification.  In each case, the important structural features of natural products are used as 
inspiration to target medicinally relevant regions of chemical space. 
Approaches to diversity-oriented synthesis fall in one of two general areas.6  In one 
strategy, structural diversity can be accomplished by modular assembly of pre-functionalized 
building blocks.  A number of structurally unique molecules is pre-made, and then assembled 
in an efficient manner in different sequences (Figure 1.2).  Functional group intolerance may 
limit this method.  Alternatively, structural diversity can be accomplished by initial assembly 
of a generic scaffold followed by late-stage incorporation of diverse functionalized subunits 
(Figure 1.3).  A synthetic strategy allowing for a readily accessible scaffold and orthogonal 
methods of functionalization are required for facile attachment of diversity elements.  
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Diversity-incorporating synthetic strategies must be able to tolerate a wide variety of 
functional groups for this method to be viable.6 
 
Figure 1.2: Diversity-Oriented Synthesis through Modular Assembly of Pre-functionalized Building Blocks 
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Figure 1.3: Diversity-Oriented Synthesis through Functionalization of Generic Scaffold 
The current work incorporates the second general strategy: modular synthesis of a 
generic scaffold followed by late-stage functionalization.  Specifically, a small library of 
orthogonally-differentiable spiroketals will be prepared.  The modular approach will allow 
for incorporation of diverse functionality at several positions around the spiroketal scaffold.  
Spiroketals were chosen because they have been extensively studied to probe the role of the 
anomeric effect as a means of controlling the three-dimensional conformation of heterocyclic 
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systems.14  The spiroketal substructure has the ability to be stabilized by the anomeric effect 
and has been suggested that it may act as a β-turn mimic in natural products.15,16  
B. Background on Spiroketals 
(i)  Structure 
The 1,7-dioxaspiro[5.5]undecane unit, also known as a 6,6-spiroketal (Figure 1.4), is 
a characteristic architectural feature in many simple and complex natural products.  
Spiroketals can be found in many classes of natural products, including insect pheromones 
and marine and fungal toxins.  Naturally occurring spiroketals are typically 6,6-spiroketals; 
however, 6,5- and 5,5-spiroketal substructures are also known.17  In the current study, the 
rigid nature of the 6,6-spiroketal unit will be utilized as a central core structure from which 
various natural product-like groups can be displayed with a specific relative orientation.  The 
possibility of interaction with potential biological targets will be investigated.   
 
Figure 1.4: A Spiroketal 
(ii) The Anomeric Effect 
The anomeric effect is an electronic stabilization unique to substituted 
tetrahydropyran rings.  In a generic substituted tetrahydropyran ring, such as 2-
methoxytetrahydropyran (5), the thermodynamically stable chair conformation places the 
methoxy substituent in the axial position, 5a (Figure 1.5).  This is a non-intuitive result as 
steric interactions with other axial substituents typically force the bulky substituents on 6-
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membered rings to prefer an equatorial orientation.  The stability of the axial conformation 
for 2-methoxytetrahydropyran can be quantified, and the conformation with the bulky 
substituent in the axial position has been determined experimentally to be more stable by 0.9 
kcal/mole.18 
 
Figure 1.5: Chair Conformations of 2-Methoxytetrahydropyran 5 
This observation persists for all 6-membered rings that contain both an endocyclic 
element with a lone pair of electrons such as oxygen or sulfur and an adjacent substituent 
bound to the 6-membered ring by an atom significantly more electronegative than carbon 
such as sulfur, oxygen, or a halogen.  Cyclic pyranoses also benefit from this stabilization 
with the exocyclic substituent at the anomeric carbon atom of pyranoses having a propensity 
to reside in the axial position.18 
Two factors explain the preference for the exocyclic electronegative substituent to 
reside in the axial orientation: (1) minimization of net dipole and (2) molecular orbital 
overlap.  The two lone pairs of electrons on the endocyclic oxygen atom impart a local dipole 
with a fixed orientation.  When the electronegative substituent is in the equatorial position, 
the local dipole of the exocyclic substituent reinforces the local dipole of the endocyclic 
oxygen atom.  This reinforcement leads to a large net dipole and a higher overall energy.19  
When the electronegative substituent is in the axial position, the local dipole of the exocyclic 
substituent serves to negate the local dipole of the endocyclic oxygen atom (Figure 1.6).  The 
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minimization of net dipole lowers the energy of the system and leads to a more stable 
molecule. 
 
Figure 1.6: Rationalization of Anomeric Effect through Dipole Stabilization 
Additionally, the anomeric stabilization can be rationalized through a molecular 
orbital argument.  The endocyclic oxygen atom has two lone pairs in sp3 orbitals. One lone 
pair of electrons is axial and one lone pair of electrons is equatorial.  When the exocyclic 
substituent is in an axial orientation, the axial lone pair of electrons on the endocyclic oxygen 
is syn-coplanar to the σ* antibonding orbital of the adjacent carbon atom and the exocyclic 
substituent, allowing for favorable orbital overlap and delocalization of the lone pair of 
electrons with the antibonding orbital (Figure 1.7).  The delocalization of a pair of electrons 
lowers the energy of the system leading to a more stable molecule.19   
 
Figure 1.7: Rationalization of Anomeric Effect through Delocalization of a Lone Pair of Electrons 
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The ratio of chair conformer with the exocyclic substituent in the axial position to the 
chair conformer with the exocyclic substituent in the equatorial position is quite dependent 
on the dielectric constant of the solvent.  For 2-methoxytetrahydropyran (5), this solvent 
effect has been quantified through 1H NMR studies of equilibrium mixtures (Table 1.1).20  As 
the dielectric constant increases, the percentage of the tetrahydropyran with an axial 2-
methoxy substituent decreases.  In nonpolar carbon tetrachloride, the percentage of the 
tetrahydropyran with an axial 2-methoxy group is 83%, and in polar acetonitrile, the 
percentage is 68%.  This observation can be rationalized given that more polar solvents can 
tolerate and stabilize a net dipole to a greater extent than nonpolar solvents.  Thus, the 
destabilization associated with the large net dipole when the exocyclic substituent is 
equatorial is relieved.   
Table 1.1: Effect of Solvent on Conformational Equilibrium for 2-Methoxytetrahydropyran 520 
 
With respect to 6,6-spiroketals, each tetrahydropyran ring contains an endocyclic 
oxygen atom and an adjacent electronegative substituent.  Each ring, therefore, has the ability 
to be stabilized by the anomeric effect.  The optimal conformation for simple spiroketals has 
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both rings in a chair conformation with each oxygen atom in an axial orientation with respect 
to the other ring.  A 6,6-spiroketal can be oriented in four possible orientations about the 
central spirocyclic carbon atom, and each orientation will be a diastereomer to the other 
orientations if the central spirocyclic carbon atom is a chiral carbon atom.  Two other 
stereoisomers have only one ring stabilized by the anomeric effect, and the fourth 
stereoisomer is not stabilized by any anomeric effects (Figure 1.8).  Most naturally occurring 
6,6-spiroketals exist in the doubly anomeric orientation.17 
 
Figure 1.8: Anomeric Stabilization of Spiroketal Diastereomers 
(iii) Biosynthesis of Spiroketals 
Biosynthetically, most naturally occurring spiroketals are constructed through 
cyclization of a dihydroxyketone precursor prepared as part of a polyketide chain (Figure 
1.9).  As such, functional groups tend to be attached at the 2- and 8-positions in naturally 
occurring spiroketals, making the stereochemical and regiochemical diversity of spiroketals 
somewhat limited.  Even with the inherent limitation of positional diversity, spiroketal-
containing natural products have shown a variety of biological activities such as antitumor,21 
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antibacterial,22 anthelmintic,23 and inhibition of auxin signal transduction,24 among others.  
This activity profile demonstrates the variety of biological targets with which spiroketals are 
able to interact. 
 
Figure 1.9: Biosynthesis of Naturally Occurring Spiroketals 
C. Present Study of Spiroketals 
(i) Spiroketals as Natural Product Mimics 
The present study intends to utilize the structural rigidity of the spiroketal scaffold to 
construct a library of natural product-like molecules utilizing diversity-oriented synthesis 
techniques.  The spiroketal library will be used to probe unique chemical space, unlikely to 
be accessed through biosynthetic routes, for biological activity.  A modular synthetic 
approach to generic spiroketal skeletons will be developed.  The modular approach will allow 
for rapid access to large quantities of minimally functionalized substituents in a variety of 
natural and unnatural substitution patterns about the spiroketal ring system (Figure 1.10).  
Each member of this small library will be a starting point for a secondary library.  By 
incorporating orthogonally differentiable substituents in the modular spiroketal synthesis, a 
large variety of diverse functional groups known to be important pharmacophores can be 
attached to the spiroketal scaffold to populate each secondary library.  In short order, a large 
number of diversely functionalized spiroketal rings can be synthesized and tested for 
biological activity.   
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Figure 1.10: Spiroketal Scaffolds Attainable through Diversity-Oriented Synthesis 
Furthermore, the structural rigidity inherent in the spiroketal system allows for an 
interesting examination of spatial relationship and its effect on biological activity.  Naturally 
occurring spiroketals typically display functionality at the 2- and 8-positions about the 
spiroketal ring.17  This relatively fixed orientation imparts a specific geometric relationship 
between functional groups.  Utilizing the modular synthetic approach to spiroketals, the 
present study will position functional groups with well defined stereochemistry at positions 
other than the 2- and 8-positions.  By introducing diverse functionality in non-natural 
positions, the present study allows for the distinct spatial presentation of a variety of 
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functional groups along specified vectors originating from novel locations around the 
spiroketal core. 
The elucidation of the structure of bistramide A, a spiroketal-containing natural 
product, complexed to the protein actin (Figure 1.11) has shown the importance of the native 
orientation of the functionality originating from the spiroketal core.  Based on the crystal 
structure data, the spiroketal seems to function only as a scaffold to orient the side chains in a 
specific manner to facilitate binding to the biological target.25  The present study aims to 
examine whether positioning functional groups in non-natural orientations around the rigid 
spiroketal scaffold will result in unique biological properties not available as a result of 
biosynthetic pathways. 
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Figure 1.11: Bistramide A Bound to Actin25 
The modular synthesis of spiroketals will incorporate a terminal alkene, an aryl 
halide, or a terminal alkyne at various positions about the spiroketal core.  These three 
functional handles, introduced early in the synthetic route, can easily be transformed into a 
wide variety of functional groups, introduced late into the synthetic route, by simple 
chemical modifications.  The alkene can be modified through olefin cross-metathesis 
reaction,26 the aryl halide by a palladium (0) catalyzed cross coupling reaction,27 and the 
alkyne by a Huisigen dipolar cycloaddition with an azide (Figure 1.12).28  Initial libraries to 
be targeted will display a diverse set of pharmacophores known for drug-target interactions.  
Side chains to be added to the spiroketal will include groups displaying a wide range of 
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pKa’s known for similarity to drug-like molecules and groups with intrinsic hydrogen 
bonding abilities.  After initial screening of a first generation library of compounds, a second 
generation library can be prepared to further elaborate on the strengths of the first generation 
library. 
 
Figure 1.12: Orthogonal Functional Handles for Spiroketal Derivatization 
(ii) The Synthesis of Milbemycin β14 
The second part of the present study involves the incorporation of this modular 
synthesis of spiroketals to the synthesis of the spiroketal-containing natural product 
milbemycin β14 7 (Figure 1.13).  Milbemycin β14 was isolated from the fermentation broth of 
a strain of Streptomyces bingchenggensis.29,30  Like other members of the milbemycin family 
and related avermectin family of natural products, milbemycin β14 possesses potent acaricidal 
and nematocidal activity.30  The synthesis of milbemycin β14 begins with preparation of the 
spiroketal unit utilizing the modular approach developed previously.  This fragment will be 
coupled to two other key retrosynthetic fragments to complete the synthesis of the natural 
product. 
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Figure 1.13: Milbemycin β14 
  
 
 
CHAPTER 2 
2.SPIROKETALS AS NATURAL PRODUCT MIMICS 
A. Proof of Concept 
(i) Retrosynthesis 
As a proof of concept for the modular synthesis of spiroketals, the first targeted 
spiroketal, 8, incorporated a terminal alkene and an aryl halide in the “naturally occurring17” 
2- and 8-positions.  Retrosynthetically, spiroketal 8 was proposed to be cyclized from the 
open chain dihydroxyketone 9 upon treatment with protic acid (Scheme 2.1).  The linear 
carbon chain would be constructed through Horner-Wadsworth-Emmons coupling31 of 
aldehyde 10 and β-ketophosphonate 11.  Each coupling partner would contain all substituents 
for one of the spiroketal rings.  Thus, any synthesized phosphonate representing one of the 
spiroketal rings can be coupled to any aldehyde representing the other spiroketal ring.  In this 
manner, spiroketal rings can be mixed and matched to create any desired spiroketal scaffold 
with any substitution pattern. 
The stereocenters of the aldehyde fragment, 10, can be set through the 
enantioselective aldol addition as developed in the Crimmins laboratory.32  The phosphonate, 
11, can be synthesized through a modified Claisen condensation of lithiated dimethyl 
methylphosphonate with ester 14.  The ester can arise from a stabilized Wittig reaction 
between a phosphorous ylide and an aldehyde, followed by subsequent diimide reduction.33  
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The stereocenters of ester 14, similar to the previous aldehyde, can be set through the 
enantioselective aldol addition as developed in the Crimmins laboratory.32 
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Scheme 2.1: Retrosynthesis of Spiroketal 8 
(ii) Synthesis of the Phosphonate Fragment 
The synthesis of the proof-of-concept spiroketal began with an Evans syn aldol 
addition32 with thiazolidinethione 13 and p-bromobenzaldehyde (15) which proceeded in 
93% yield and a 16:1 diastereomeric ratio (Scheme 2.2).  Silyl protection of the secondary 
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alcohol followed by reductive cleavage of the chiral auxiliary to the aldehyde by 
diisobutylaluminum hydride gave aldehyde 17 in 89% yield over two steps. 
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Scheme 2.2: Synthesis of Phosphonate 11 
Wittig olefination of the aldehyde with ethyl (triphenylphosphoranylidene)acetate 
(18) yielded the unsaturated ester in 92% yield.  Subsequent diimide reduction33 by treatment 
with tosylhydrazine and aqueous sodium acetate in refluxing dimethoxyethane provided 89% 
yield of ethyl ester 14.  Completion of the β-ketophosphonate fragment required lithiation of 
dimethyl methylphosphonate (19) and modified Claisen condensation with the ethyl ester 
previously prepared.  Initial yields for the modified Claisen condensation were inconsistent.  
After optimization, pre-cooling of the base in a jacketed addition funnel prior to addition to 
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phosphonate 19, followed by addition of the ester – pre-cooled in the same jacketed addition 
funnel, resulted in clean reaction.  Phosphonate 11 was isolated in 98% yield using this 
method.  Multigram quantities of β-ketophosphonate 11 could be produced in 66% yield over 
six steps and stored indefinitely. 
(iii) Synthesis of the Aldehyde Fragment 
Synthesis of the aldehyde coupling partner for the Horner-Wadsworth-Emmons 
reaction commenced with another Evans syn aldol addition32 between thiazolidinethione 13 
and 3-butenal (20)34 (Scheme 2.3).  Silyl protection of the secondary alcohol followed by 
reductive cleavage of the chiral auxiliary with diisobutylaluminum hydride gave aldehyde 10 
in 61% yield over two steps.  The aldehyde coupling partner was thus completed on gram 
scale in 3 steps and 56% overall yield. 
 
Scheme 2.3: Synthesis of Aldehyde 10 
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(iv) Completion of the Spiroketal Scaffold 
Horner-Wadsworth-Emmons coupling of aldehyde 10 and β-ketophosphonate 11 
using barium hydroxide as a mild base31 required vigorous stirring to ensure adequate mixing 
of the reaction solution, giving the unsaturated ketone in 83% yield (Scheme 2.4).  Reduction 
of the enone olefin in the presence of the terminal olefin was completed using 
diisobutylaluminum hydride with hexamethylphosphoramide and catalytic methyl copper as 
an additive,35 providing saturated ketone 22 in 91% yield without over-reduction.  To access 
spiroketal 8, the silyl ether protective groups were removed with tetrabutylammonium 
fluoride in quantitative yield, giving the open chain dihydroxyketone.  Treatment with 
pyridinium p-toluenesulfonate closed the dihydroxyketone to the desired spiroketal 8 in 86% 
yield, providing proof of concept.  The entire synthesis of the spiroketal required 10 longest-
linear steps and provided gram quantities of the desired spiroketal scaffold in 43% overall 
yield. 
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Scheme 2.4: Completion of Spiroketal 8 
(v) Stereochemical Analysis using 2-D NMR 
The rigid scaffold characteristic of spiroketals enables facile confirmation of the 
orientation of the spirocycle based on observation of the through-space interactions of nearby 
protons.  Specifically, nuclear Overhauser effects (nOe) utilizing NOESY experiments can be 
instrumental in structural confirmation of polycyclic molecules.  The 2-D NOESY analysis 
confirmed the three dimensional conformation of spiroketal 8 as the doubly anomeric 
spiroketal.  Four possible spiroketal conformations are theoretically possible.17  In the doubly 
anomeric diastereomer of spiroketal 8, the two protons on carbinol carbon atoms, Ha and Hb, 
are positioned in close proximity to each other.  This orientation is exclusive to the doubly 
anomeric spiroketal; thus, detectable interaction between the protons on the carbinol carbon 
atoms constitutes proof of the correct spiroketal geometry.  Interaction between protons Ha 
and Hb was indeed detected (Figure 2.1), demonstrating the major spiroketal formed from the 
cyclization of the dihydroxyketone was indeed the desired doubly anomeric spiroketal. 
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Figure 2.1: NOESY Signals for Spiroketal 8 
B. Synthesis of Unnatural Spiroketal Scaffold 23 
(i) Synthesis of the Aldehyde Fragment 
Spiroketal 23, the first unnaturally substituted spiroketal scaffold targeted, 
incorporated the terminal alkene in the 3-position of the spiroketal while keeping the aryl 
halide in the 8-position (Figure 2.2).  The synthesis of spiroketal 23 was expected to follow 
the same course as the previous spiroketal and required the preparation of an aldehyde and a 
β-ketophosphonate.  Leaving the aryl halide in the same position was strategic as the β-
ketophosphonate fragment, 11, had already been synthesized in the preparation of the first 
spiroketal.  Only the new aldehyde coupling partner, 24, needed to be synthesized.   
 
Figure 2.2: Unnatural Spiroketal 23 
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A modified thiazolidinethione starting material was synthesized through coupling of 
4-pentenoic acid (26) and free auxiliary 25 in 79% yield.  Evans syn aldol addition32 with 
acetaldehyde proved difficult due to trimerization of the aldehyde.  Depolymerization prior to 
use proved unsuccessful.  Conducting the reaction with a previously unopened bottle of 
acetaldehyde resulted in 54% yield of the desired aldol adduct 28 (87% based on recovery of 
thiazolidinethione starting material) as a 10:1 mixture of diastereomers (Scheme 2.5).  
Alcohol protection and reduction of the auxiliary to the aldehyde proceeded uneventfully to 
provide the desired aldehyde coupling partner 24 in 84% yield over two steps, and 45% 
overall yield over three steps from thiazolidinethione 27. 
 
Scheme 2.5: Synthesis of Aldehyde 24 
(ii) Completion of the Spiroketal Scaffold 
Horner-Wadsworth-Emmons coupling31 of aldehyde 24 with the previously prepared 
β-ketophosphonate 11 resulted in 71% yield of the unsaturated ketone (Scheme 2.6).  
Copper-mediated selective 1,4-hydride reduction35 proceeded in 94% yield, providing the 
bis-protected dihydroxyketone 29.   
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With the dihydroxyketone in hand, the key cyclization to form spiroketal 23 was 
investigated.  One pot deprotection/cyclization with hydrofluoric acid in either acetonitrile or 
tetrahydrofuran at room temperature resulted in an inseparable 13:1 mixture of unknown 
spiroketals arbitrarily labeled A and B.  Interestingly, pyridinium p-toluenesulfonate 
catalyzed cyclization of the deprotected diol at room temperature formed an inseparable 1:3 
mixture of the same two spiroketals A and B, this time with reversed selectivity favoring B.  
The 1-D proton NMR of the mixture did not reveal which spiroketal was formed 
preferentially.  However, given the plausibility of the various cyclization reaction 
mechanisms, two competing spiroketal products are likely to be formed in the cyclization.  
The desired spiroketal 23a benefits from two anomeric stabilizations, but suffers from steric 
hindrance associated with the axially oriented terminal alkene substituent.  Alternatively, a 
second spiroketal, 23b, could be formed that only benefits from one anomeric stabilization, 
but the terminal alkene is now in the more stable equatorial position. 
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Scheme 2.6: Completion of the Spiroketal Scaffold 
(iii) Elucidation of the Spiroketal Mixture 
Experiments were undertaken to attempt to form one of the spiroketals exclusively 
(Table 2.1).  One pot deprotection/cyclization with hydrofluoric acid at 70 °C resulted in 
decomposition of the reaction mixture.  The same reaction conditions at -78 °C resulted in 
the most selective conditions, a 17:1 mixture of the inseparable spiroketals favoring 
spiroketal A.  PPTS cyclization of the deprotected diol at -78 °C yielded a 1:2 mixture of 
spiroketals favoring B, while the same reaction conditions at 70 °C reversed the selectivity 
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giving a 6:1 mixture of spiroketals favoring A.  Thus, it would appear that unknown 
spiroketal A might be the thermodynamically stable spiroketal, and spiroketal B might be the 
kinetically formed spiroketal based on differences in reaction temperature and acid strength. 
Table 2.1: Survey of Spiroketalization Conditions 
 
As each step in the formation of the spiroketal is reversible, attempts were made to 
equilibrate the spiroketal mixtures to bias one spiroketal over the other.  Thermal 
equilibration without catalyst at 40 °C of the mixture favoring spiroketal A did not change 
the ratio of spiroketals, while thermal equilibration without catalyst of the mixture favoring B 
re-equilibrated the mixture to a 1:1.6 mixture favoring spiroketal B.  Interestingly, 
equilibration of both mixtures with camphorsulfonic acid at 40 °C resulted in a 8:1 mixture 
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of spiroketals both favoring spiroketal A.  These results seem to confirm the observation that 
spiroketal A is the thermodynamically favorable spiroketal. 
Based on the thermodynamics of the anomeric stabilization, it was predicted that the 
doubly anomeric spiroketal should be the thermodynamically favorable spiroketal, in spite of 
the associated steric strain of the axially oriented terminal alkene group.  As with the 
previously prepared spiroketal, 2-D NMR was used to aid in the elucidation of the absolute 
configuration of spiroketals A and B.  If spiroketal A is the desired spiroketal, the two 
protons on the carbinol carbon atoms, Ha and Hb, should show a strong nOe signal in the 
NOESY experiment.  Unfortunately, when the 13:1 mixture of spiroketals favoring spiroketal 
A was analyzed by 2-D NOESY NMR, no nOe signal between Ha and Hb was observed. 
The lack of a nOe signal between the characteristic protons does not necessarily 
indicate that spiroketal A is not the desired spiroketal.  A slight torque of the spiroketal ring 
as a result of the axial substituent could push the two protons on the carbinol carbon atoms 
far enough away from each other that the distance is too large to result in an nOe signal.  
However, it was noticed in the same 2-D NMR spectrum of the mixture favoring spiroketal A 
that an nOe signal between one set of aryl protons, Hc, and both methyl groups was observed 
(Figure 2.3).  One of these nOe signals is expected as the aryl substituent is adjacent to one of 
the methyl substituents.  The other nOe signal is not expected in the desired spiroketal.  
Instead, the undesired, singly anomeric spiroketal, 23b, with both bulky substituents 
equatorial can account for the nOe signals observed in the 2-D NOESY NMR (Figure 2.3).  
In singly anomeric spiroketal 23b, the two protons on the carbinol carbon atoms, Ha and Hb, 
are on opposite sides of the spiroketal and are not expected to show an nOe signal.  
Additionally, both methyl groups are now in the vicinity of the aryl protons Hc, in agreement 
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with the observed positive nOe signal.  Based on this evidence, the undesired, singly 
anomeric spiroketal 23b was assigned as spiroketal A, the major product of one-pot 
deprotection/cyclization with hydrofluoric acid. 
 
Figure 2.3: NOESY Signals for Spiroketal 23 
NOESY data was also collected for the mixture that favored spiroketal B (Figure 2.4).  
The most striking observation was the nOe signal between the two protons on the carbinol 
carbon atoms, Ha and Hb.  This is the signal expected for the doubly anomeric spiroketal 23a.  
Furthermore, the aryl protons Hc which showed positive correlation to the two methyl groups 
in spiroketal A now only showed correlation to the methyl group adjacent to the aryl group in 
spiroketal B.  Based on this evidence, the desired, doubly anomeric spiroketal 23a is 
spiroketal B produced in minor quantities.  Interestingly, it appears the energetic 
destabilization of the axially oriented terminal alkene group is greater than the energetic 
stabilization associated with the two anomeric effects. 
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Figure 2.4: NOESY Signals for Spiroketal 23 
C. Second Generation Synthesis of Unnatural Spiroketal Scaffold 34 
(i) Synthesis of the Spiroketal Scaffold and Structural Elucidation 
In the current system, desired spiroketal B (23a) is produced in minor quantities, and 
equilibration experiments only successfully altered the ratio of products further toward the 
undesired spiroketal A (23b).  Spiroketal A is undesired not because it is singly anomeric, 
but because the vector relationship between the main substituents is now in the same 
orientation as in naturally occurring spiroketals.  This defeats the purpose of moving the 
spiroketal substituent to a new location.  In order to bias the equilibrium back toward the 
desired, doubly anomeric spiroketal 23a, spiroketal A needed be destabilized enough to allow 
spiroketal B to be thermodynamically favored.  If the axial methyl group adjacent to the 
terminal alkene were made larger, steric destabilization of spiroketal A is predicted to be 
large enough to change the favored spiroketal diastereomer to favor spiroketal B.  The 
spiroketal which replaces the methyl group with an isopropyl group, 34, was targeted. 
The synthesis of the bulkier spiroketal 34 commenced with an Evans syn aldol 
addition32 with the modified thiazolidinethione 27 and isobutyraldehyde (30).  Use of 
isobutyraldehyde alleviated the problems associated with use of acetaldehyde previously, and 
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aldol adduct 31 was produced in 69% yield as a single diastereomer (Scheme 2.7).  Silyl 
ether protection of the secondary alcohol and reduction of the chiral auxiliary to the aldehyde 
provided aldehyde 32 in 64% yield over two steps.  Horner-Wadsworth-Emmons coupling 
with β-ketophosphonate 11 synthesized previously followed by selective 1,4-reduction 
provided protected ketone 33 in 76% yield over two steps. 
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Scheme 2.7: Synthesis of Spiroketal 34 
Removal of the protective groups and cyclization under acidic conditions would 
complete the synthesis of spiroketal 34.  Gratifyingly, one-pot deprotection and cyclization 
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with hydrofluoric acid provided a single spiroketal with complete selectivity, arbitrarily 
called spiroketal C.  Interestingly, PPTS cyclization of the deprotected diol provided a 
different spiroketal, spiroketal D, also with complete selectivity.  As with the previous 
system, two possible spiroketals were predicted to form from the cyclization reaction.  
NOESY analysis was carried out on each spiroketal to determine the three-dimensional 
orientation.  Spiroketal C, obtained from cyclization with hydrofluoric acid, unfortunately did 
not show an nOe signal between the two protons on the carbinol carbon atoms, Ha and Hb, as 
would be expected from the desired, doubly anomeric spiroketal.  Furthermore, spiroketal D, 
obtained from PPTS cyclization, also did not show an nOe signal between the characteristic 
protons Ha and Hb, implying neither of the completely selective cyclization strategies 
produced the desired spiroketal. 
On further analysis of the 2-D NOESY spectra for spiroketal C, obtained from 
cyclization with hydrofluoric acid, an nOe signal was noted between the proton on the aryl 
carbinol carbon, Hb, and the methyl protons of the isopropyl group.  This is not expected with 
either the desired or undesired spiroketals predicted to form in the reaction.  Simple MM2 
calculations indicated that both spiroketals were relatively high in energy due to bulky 
substituents occupying an axial position in each of the spiroketal diastereomers.  Further 
MM2 calculations indicated a lower energy structure that accounted for the observed 
NOESY signals in the hydrofluoric acid-cyclized spiroketal.  The 6-membered ring with the 
isopropyl group and the terminal alkene was not in the desired chair conformation.  Instead, 
spiroketal C did turn out to be the doubly anomeric spiroketal, but with one of the rings in a 
boat conformation.  In the boat conformation, the nOe signal between the proton on the aryl 
carbinol carbon atom, Hb, and the methyl protons on the isopropyl group is expected.  
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Spiroketals with one ring not residing in a chair conformation, while rare, are known in the 
literature.36–39  Even though the doubly anomeric spiroketal was formed, the undesired 
conformation failed to meet the goals of predictable and specified vector relationships 
between the functionalized substituents. 
 
Figure 2.5: NOESY Signals for Spiroketal C 
The NOESY spectrum for spiroketal D from the PPTS cyclization was analyzed 
further to attempt to identify the conformation of this spiroketal (Figure 2.6).  The presence 
of nOe signals between the aryl protons, Hc, and both the methyl protons of the isopropyl 
group and the proton on the carbinol carbon atom, Ha, adjacent to the isopropyl group 
continues to be a source of confusion.  Correlation between the aryl proton and methyl proton 
on the isopropyl group is expected in the singly anomeric spiroketal, but correlation with the 
proton on the carbinol carbon atom is not.  The absolute configuration of this spiroketal has 
still not been determined unambiguously; however, it is clear that it is not the desired 
spiroketal in the desired conformation.   
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Figure 2.6: NOESY Signals for Spiroketal D 
While the spatial relationship goals of the project were not met, the successful 
modular synthesis of spiroketals provided several interesting insights into the inherent 
stability of the anomeric effect when challenged by other destabilizing elements elsewhere in 
the molecule.  Steric interactions, such as those imparted by axially oriented substituents, are 
well known to alter the conformational bias of spiroketals and cause singly anomeric 
diastereomers to become the lowest energy product of spiroketalization;17,14 however, 
changing the diastereomeric ratio is typically the resolution to the problem of steric 
hindrance – as seen with spiroketal 23.  It is rare to see one of the pyran rings abandon a 
chair conformation in favor of a boat conformation, as seen with spiroketal 34.  It was 
decided to change directions and utilize the modular synthesis of spiroketals in the synthesis 
of spiroketal-containing natural product milbemycin β14. 
 
  
 
 
CHAPTER 3 
3.PROGRESS TOWARD THE TOTAL SYNTHESIS OF MILBEMYCIN Β14 
A. Background on Milbemycin β14 
(i) Isolation and Structural Features of Milbemycins 
In 1975, a class of structurally unique macrolides was isolated as metabolites of 
Streptomyces B-41-146 by Mishima and coworkers from a soil sample from Japan.40  
Thirteen compounds were identified in the original isolation paper and were termed the 
milbemycins.  Over the next several years, the number of isolated milbemycins 
expanded,41,42 and to date more than thirty milbemycin natural products have been isolated 
and identified.  Milbemycins are potent antiparasitic, anthelmintic, and insecticidal agents, 
without showing significant toxicity to plants or animals.40  Additionally, a structurally 
related class of natural products, the avermectins, was isolated in 1979 from a strain of 
Streptomyces avermitilis.43  The avermectins exhibit a similarly impressive biological profile.  
Specifically, ivermectin,44 a semisynthetic avermectin derivative has proven to be widely 
successful in the treatment of onchocerciasis (“river blindness”).45,46 
The milbemycins lack a systematic nomenclature system, but structurally, all 
milbemycins contain a 16-membered macrolactone and a spiroketal.  In general, the α-
designated milbemycins contain a hexahydrobenzofuran subunit, with three of those carbon 
atoms involved in the macrolactone (Table 3.1).  In contrast, the β-designated milbemycins 
contain a monocyclic southern fragment as either a cyclohexene ring (Table 3.2) or an 
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aromatic ring (Table 3.3).  The milbemycins differ from the avermectins in substitution at the 
C-13 carbon atom.  The avermectins contain a disaccharide at the C-13 position, while the 
milbemycins are unsubstituted at C-13.  The structures of the first milbemycins were 
determined by a combination of 1H NMR, 13C NMR, mass spectrometry, and infrared 
spectroscopy data.40  Additionally, chemical derivatization of milbemycin β1 as a p-
bromophenylurethane derivative provided crystals suitable for x-ray crystallographic 
analysis.  Absolute configuration of the milbemycins was obtained by chemical conversion 
of milbemycin D to an avermectin aglycon whose absolute configuration had been previously 
assigned.47 
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Table 3.1: Milbemycin Natural Products Containing Hexahydrobenzofuran Subunit 
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Table 3.2: Milbemycin Natural Products Containing Cyclohexene Subunit 
 
Table 3.3: Natural Products Containing Aromatic Subunit 
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Isotopic enrichment of various feed chemicals in the fermentation broth provided 
evidence that the carbon skeleton is biosynthetically composed of seven acetate units and 
five propionate units (Figure 3.1).48  The substitution at C-25 can originate from acetate, 
propionate, isobutyrate or DL-valine.  Methionine is responsible for providing the methyl 
group at carbon 5 in milbemycins with a C-5 methoxy group.  Isotopic labeling of oxygen 
showed that the oxygen atoms are incorporated from corresponding acetate and propionate 
units, with the exception of the endocyclic tetrahydrofuran oxygen atom in the α-series.  
Introduction of isotopically labeled molecular oxygen proved that oxygen atom to be derived 
from atmospheric oxygen. 
 
Figure 3.1: Biosynthetic Origins of Milbemycin α2 
Due to the potent biological profile and the interesting structural complexity, the 
milbemycins have been a frequent target of total synthesis.  The first total synthesis of (±)-
milbemycin β3 was reported by Smith in 1982.49  Williams reported the first enantioselective 
synthesis shortly thereafter.50  Milbemycin β3 has been a popular target of publication, with 
ten total syntheses49–58 and four formal syntheses.59–62  Other milbemycin natural products 
have been the targets of total synthesis, including milbemycin α1,63,64 milbemycin D,65 
milbemycin E,66,67 milbemycin G,68,69 and milbemycin β1.70,71  The Crimmins laboratory has 
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contributed significantly to the syntheses of the milbemycins and avermectins, publishing 
several fragment syntheses,72–75 a formal synthesis of milbemycin β361 and the first total 
asymmetric synthesis of milbemycin D.65 
(ii) Isolation and Properties of Milbemycin β14 
In 2007, the Wang group at Northeast Agricultural University in China isolated two 
new milbemycins from the fermentation broth of a strain of Streptomyces bingchenggensis.30  
From 10 L of the fermentation broth, 25 g of crude extracts were isolated.  After extensive 
chromatography, 18 mg of milbemycin β13, 35, and 50 mg of milbemycin β14, 7, (Figure 3.2) 
were isolated.  The structures were elucidated based on IR spectroscopy data, 1H NMR and 
13C NMR spectroscopy data, mass spectrometry data, and spectroscopic correlation to known 
milbemycin β3.  Both milbemycin β13 and β14 show potent acaricidal (Table 3.4) and 
nematocidal (Table 3.5) activity.  Furthermore, the two new metabolites were more active 
than known milbemycins against unhatched mite eggs.30  To date no synthesis of milbemycin 
β14 has been reported. 
 
Figure 3.2: Milbemycins β13 and β14 
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Table 3.4: Acaricidal Activity of Milbemycins against Adult Mites and Mite Eggs 
 
Table 3.5: Nematocidal Activity of Milbemycins against Caenorhabditis elegans 
 
B. Synthesis of Milbemycin β14 
(i) Original Retrosynthesis 
Retrosynthetically, the natural product 7 was envisioned to be disconnected into three 
key fragments: spiroketal 37, chiral alcohol 36, and achiral aromatic phosphine oxide 38 
(Scheme 3.1).  The chiral alcohol 36 was envisioned to come from an enantioselective 
alkylation utilizing an oxazolidinone, 40, derived from norephedrine.76  The phosphine oxide, 
38, could arise from SN2′ addition of a lithiated phosphine to the substituted 
isobenzofuranone 41.54  Isobenzofuranone 41 was expected to arise from vinyl Grignard 
addition to hydroxyacetophenone derivative 42, which was expected to come from anisic 
acid derivative 43. 
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Scheme 3.1: Retrosynthesis of Milbemycin β14 
Drawing from successes in the previous project, the modular synthesis of spiroketals 
was adapted for use in the synthesis of spiroketal fragment, 37, of milbemycin β14.  The 
spiroketal was expected to arise from protected triol 44 (Scheme 3.2).  The triol can be 
synthesized through Horner-Wadsworth-Emmons31 coupling of β-ketophosphonate 46 and 
aldehyde 45.  The stereocenters of aldehyde 45 were predicted to be set by an Evans anti 
aldol addition77 with oxazolidinone 47.  The stereocenters of β-ketophosphonate 46 could 
arise from a series of iterative acetate aldol addition reactions78 with mesityl-substituted 
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thiazolidinethione auxiliaries 50 and 51. The synthesis of the spiroketal fragment was 
investigated first. 
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Scheme 3.2: Retrosynthesis of the Spiroketal Fragment of Milbemycin β14 
(ii) Synthesis of the Spiroketal Fragment 
The synthesis of the spiroketal fragment, 37, commenced with acetate aldol addition78 
of 3-butenal (20)34 and thiazolidinethione 51 (Scheme 3.3).  The aldol adduct 53 was 
prepared in 80% yield and better than 20:1 mixture of diastereomers.  Silyl protection of the 
secondary alcohol and reductive cleavage of the chiral auxiliary provided aldehyde 54 in 
75% yield over two steps.  The second acetate aldol addition proved surprisingly difficult.  
Aldol addition under standard conditions78 led to deprotection of the silyl ether protective 
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group and poor yield.  Buffering the reaction with excess Hünig’s base79 resulted in retention 
of the protective group but poor overall yield, possibly due to the presence of acidic α-
protons on the chiral aldehyde.   
 
Scheme 3.3: Initial Iterative Aldol Attempt 
Successful iterative aldol sequence was realized by changing the original protective 
group to a t-butyldimethylsilyl ether.  Silyl protection of the original aldol adduct 53 as t-
butyldimethylsilyl ether 56 and subsequent reduction provided aldehyde 57 in 66% yield 
over two steps (Scheme 3.4).  The second acetate aldol addition78 with thiazolidinethione 50 
of the opposite enantiomer provided iterative aldol adduct 58 in 54% yield as a single 
stereoisomer.  Silyl protection of the secondary alcohol and direct displacement of the 
auxiliary with lithiated dimethyl methylphosphonate (19) provided β-ketophosphonate 60 in 
83% yield over two steps.  The phosphonate fragment was synthesized in 6 steps and 24% 
overall yield. 
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Scheme 3.4: Successful Iterative Aldol Addition Sequence 
Anti aldol addition of propionate oxazolidinones with unsaturated aldehydes is well 
precedented, while anti aldol addition fails with enolizable aldehydes.77  Unfortunately, all 
attempts to use acrolein (48) in an anti aldol addition failed (Scheme 3.5).  While anti aldol 
addition with methacrolein is a known reaction in the original methodology paper,77 the 
corresponding reaction with acrolein is not reported.  Standard conditions with catalytic 
magnesium chloride resulted in only 92% recovered starting material.  Increasing Lewis acid 
amount to one equivalent also resulted in recovery of starting material.  The same anti 
relationship can be realized with the opposite enantiomer of thiazolidinethione auxiliary and 
magnesium bromide as Lewis acid.80  As with the oxazolidinone system, use of 
thiazolidinethione 62 with catalytic magnesium bromide resulted in near quantitative 
recovery of starting material.  The only conditions which resulted in isolation of product 
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involved catalytic magnesium bromide with the thiazolidinethione starting material after 
reaction for seven days.  The product 63 was isolated in 27% yield and 60% additional 
recovery of starting material. 
 
Scheme 3.5: Anti Aldol Attempts 
The aldehyde was eventually realized through a multistep Frater-Seebach alkylation 
strategy.81  Acetate aldol addition78 of propionaldehyde (64) with thiazolidinethione 51 
resulted in 89% of aldol adduct 65 as a single stereoisomer (Scheme 3.6).  Direct 
displacement of the auxiliary with isobutanol82 yielded β-hydroxy ester 66.  Double lithiation 
of the hydroxy ester with lithium diisopropylamide and alkylation with methyl iodide81 
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yielded α-methyl ester 67 in 55% yield as an 8.5:1 mixture of anti:syn diastereomers.  The 
secondary alcohol of the desired anti diastereomer was protected as silyl ether 68 in 96% 
yield.  Reduction of the ester with diisobutylaluminum hydride provided 68% yield of the 
desired aldehyde 45 and 30% yield of over-reduced alcohol 69.  Oxidation of the primary 
alcohol to the aldehyde with Dess-Martin periodinane yielded the aldehyde in 62% yield, 
resulting in an 87% total yield of aldehyde 45 from ester 68.  The aldehyde was prepared in 6 
steps and 15% overall yield. 
 
Scheme 3.6: Frater-Seebach Approach to Aldehyde 45 
The anti configuration of the Frater-Seebach product was confirmed through 
derivatization of the methylated product.  Some of the over-reduced alcohol 69 from 
reduction of ester 68 was deprotected with tetrabutylammonium fluoride to give the 
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deprotected diol (Scheme 3.7).  Acetal formation with p-methoxybenzaldehyde dimethyl 
acetal 70 under acidic conditions provided the cyclic acetal 71.  NOESY analysis of the 
cyclic acetal showed positive correlation between proton He on the acetal carbon atom, the 
axial methylene proton Hb and the axial methine proton Hd.  Additionally, positive 
correlation between axial methine proton Hc and the equatorial methylene proton Ha was 
noticed.  Importantly, no correlation between the axial methine proton Hc and either of the 
neighboring axial protons, Hb and Hd, was observed.  Based on the observed and absent 
signals in the 2-D analysis of acetal 71 the anti configuration of the Frater-Seebach alkylation 
product was confirmed. 
 
Scheme 3.7: Confirmation of Anti Stereochemistry of Frater-Seebach Product 
Further analysis of the desired aldehyde indicated the product could be made in a 
more straightforward manner.  The desired aldehyde is a dimer of propionaldehyde, and as 
such can be synthesized through an organocatalytic anti aldol addition as developed by 
MacMillan.83  Propionaldehyde (64) was dimerized with a catalytic amount of unnatural D-
proline in dimethylformamide (Scheme 3.8).  After the reaction was complete, addition of 
imidazole and t-butylchlorodimethylsilane provided the protected anti aldol addition product 
in one pot and in 33% yield to give aldehyde 72 directly.  While the yield is low, it is higher 
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than the overall yield from the six-step Frater-Seebach route and can easily be scaled to 
multigram quantities. 
 
Scheme 3.8: Organocatalytic Synthesis of Aldehyde 72 
With the protected aldehyde 72 in hand, Horner-Wadsworth-Emmons coupling31 with 
β-ketophosphonate 60 provided the unsaturated ketone in 88% yield (Scheme 3.9).  Selective 
1,4-reduction35 of the enone followed by one-pot deprotection and cyclization gave a single 
spiroketal 74 in 46% yield over two steps.  The two steps encompass five transformations 
including enone reduction, three silyl ether deprotections, and diastereoselective ketal 
formation.  The spiroketal was analyzed by 2-D NOESY NMR.  NOE signals were observed 
between the three axial protons on all three carbinol carbon atoms, indicating the desired 
spiroketal 74 was the major product of the cyclization reaction.  Spiroketal 74 was completed 
in 9 overall steps (longest linear sequence) and 18% overall yield. 
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Scheme 3.9: Completion of the Spiroketal Fragment 74 
(iii) Synthesis of the Chiral Alcohol Fragment and Completion of the Northern Fragment 
The second key retrosynthetic target 36 contained the 1,1-disubstitued olefin and the 
final stereocenter in the molecule.  This fragment would be connected to the spiroketal 
fragment through ruthenium-catalyzed cross metathesis26 and to the phosphine oxide 
fragment through Horner-Wadsworth-Emmons coupling.54  Preparation of the fragment 
containing the distal stereocenter began with stereoselective alkylation of lithiated 
oxazolidinone 40, derived from norephedrine, with methallyl iodide (39)76 to give alkene 75 
in 56% yield as a single diastereomer (Scheme 3.10).  Lithium aluminum hydride reduction 
of imide 75 to primary alcohol 36 was achieved in 57% yield.  The fragment was ready to be 
coupled to the spiroketal, and a series of cross metathesis studies were undertaken. 
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Scheme 3.10: Synthesis of the Distal Stereocenter Fragment 36 
At room temperature in both dichloromethane and benzene, Grubbs 2nd generation 
catalyst 76 (G2) failed to couple the two fragments, and the starting materials remained 
unchanged throughout the reaction (Table 3.6, Entries 1–2).  At elevated temperatures in 
dichloromethane (Entry 3), G2 also failed to couple the fragments; however, the spiroketal 
was transformed into some unidentifiable byproduct.  Dimerization studies were undertaken 
(Entry 4), and with G2 or HG2 (Hoveyda-Grubbs 2nd generation catalyst 77) the spiroketal 
could be dimerized in toluene at 80 °C in the absence of the 1,1-disubstitued olefin and 
isolated.  To see if the dimer was consumable, the spiroketal was pre-dimerized with G2 or 
HG2 in toluene at 80 °C (Entry 5), followed by addition of the 1,1-disubstituted olefin.  Only 
dimer was recovered with each catalyst.  Similarly starting with isolated and purified 
spiroketal dimer (Entry 6), attempted metathesis with G2 in toluene at 100 °C resulted only 
in recovery of dimer. 
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Table 3.6: Survey of Cross Metathesis Conditions 
 
In each case, evaporation of the solvent also led to evaporation of the low-boiling 1,1-
disubstituted olefin 36.  To aid in recovery of starting material, as well as to attempt to 
modulate the activity of the 1,1-disubstituted olefin, cross metathesis studies were undertaken 
with 1,1-disubstituted olefin 75 still bound to the auxiliary.  At 1:1 stoichiometry with both 
G2 and HG2 in toluene at 80 °C (Entry 7), the 1,1-disubstituted olefin was recovered 
unchanged and the spiroketal was transformed to an unidentified product.  The unidentified 
product, upon analysis of the 1H NMR spectra, contains peaks corresponding to the 
spiroketal – without the terminal olefin peaks – and deacylated oxazolidinone auxiliary.  
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Unambiguous confirmation of the structure of this product was not obtained.  Increasing the 
equivalents of the 1,1-disubstitued fragment to 2.5:1 and 5:1 resulted in the same products 
being formed (Entry 8). 
Literature precedent84 for other cross metatheses with 1,1-disubstituted olefins 
indicates that rate of cross metathesis can be increased if an allylic or homoallylic alcohol is 
protected as a benzoate ester.  The current 1,1-disubstitued olefin fragment has an alcohol 
functional group three carbon atoms away from the alkene.  Even though metathesis of 1,1-
disubstituted olefins is not precedented with this length tether between the alkene and a 
benzoate-protected alcohol, the primary alcohol 36 was protected as benzoate ester 78 
(Scheme 3.11).  The benzoate protected 1,1-disubstituted olefin and the spiroketal were 
reacted at 5:1 stoichiometry with HG2 in toluene at 80 °C overnight (Table 3.6, Entry 9).  
The isolated material was not clean by 1H NMR, but mass spectrometry confirmed a 
compound with the mass corresponding to the coupled product was present.  
Encouraged by these results, the reaction was repeated with TBS-protected spiroketal 
37 and G2 catalyst at 80 °C overnight in toluene (Entry 10).  Spiroketal dimer was isolated, 
as well as clean coupled product.  To decrease the likelihood of spiroketal dimerization and 
increase probability of product formation, the spiroketal was added to a heated mixture of 
1,1-disubstituted olefin and catalyst (Entry 11).  Under these conditions, no dimer was 
formed, but the catalyst decomposed before cross metathesis could occur.  Thus, five 
equivalents of the 1,1-disubstituted olefin were heated in toluene at 80 °C, and the spiroketal 
and catalyst were simultaneously added to the reaction mixture dropwise from separate 
syringes (Entry 12).  Under these reaction conditions, excess 1,1-disubstituted olefin was 
recovered along with clean coupled product 79, in a 45% yield as a 2:1 mixture of alkene 
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isomers.  Separation of the alkene isomers and 2D NOESY NMR analysis provided 
confirmation that the major product of the cross metathesis reaction was the desired E olefin.  
The benzoate protecting group was removed under basic conditions to yield the primary 
alcohol in 96% yield (Scheme 3.11).  Finally, the primary alcohol could be oxidized with 
Dess Martin periodinane in quantitative yield to complete the synthesis of the northern 
fragment aldehyde 80 in 13 longest linear steps and 7.9% overall yield. 
 
Scheme 3.11: Completion of the Northern Fragment 
(iv) Efforts toward the Synthesis of the Southern Fragment 
The synthesis of southern fragment phosphine oxide 38 (Figure 3.3) proved 
surprisingly difficult.  Several syntheses of different milbemycins have been reported, and 
various strategies toward the synthesis of the southern fragment have been outlined.  
Synthesis of milbemycins belonging to the α series are not applicable to the current synthesis, 
as the hexahydrobenzofuran strategies cannot be utilized in the synthesis of the aromatic unit 
in milbemycin β14.  Additionally, most of the β series milbemycins also lack the aromatic 
 56 
 
unit.  Essentially, the only literature precedent which can be consulted is previous syntheses 
of the milbemycin β3 southern fragment. 
 
Figure 3.3: Southern Fragment Phosphine Oxide 38 
The first total synthesis of racemic milbemycin β3 by Smith49 targeted a southern 
fragment phosphine oxide 84 for use in a Wittig olefination.  Protection of 3-methyl-p-anisic 
acid (43) as the oxazoline 8154 provided a strong ortho-lithiation director (Scheme 3.14).  
Lithiation with butyllithium proceeded regioselectively ortho to the oxazoline, and inverse 
addition into acetic anhydride provided methyl ketone 82 as a single regioisomer.  Addition 
of vinyl Grignard and treatment with strong acid yielded substituted isobenzofuranone 83.  
The southern fragment was completed with SN2′ addition of lithiated diphenyl phosphine to 
provide, after autoxidation and methylation, phosphine oxide 84.  Several subsequent 
syntheses would rely on this route to complete the southern fragment.52,58  
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Scheme 3.12: Smith's Approach to Southern Fragment Phosphine Oxide 84 
Baker’s synthesis of the southern fragment51 draws inspiration from Smith’s 
synthesis, but targets an aldehyde 86 for use in a Julia olefination instead of a phosphine 
oxide.  Baker synthesizes methyl ketone 82 in the same manner as Smith, but adds allyl 
Grignard instead of vinyl Grignard to yield a related isobenzofuranone 85.  Ozonolysis, 
elimination and methylation completes the synthesis of the southern fragment aldehyde 86. 
 
Scheme 3.13: Baker's Approach to Southern Fragment Aldehyde 86 
Williams’ original enantioselective synthesis50 relies on benzylic deprotonation of 
ethyl-substituted benzoic acid derivative 88.  The benzoic acid derivative is prepared by 
double deprotonation of methyl-substituted benzoic acid derivative 87 and methylation with 
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dimethyl sulfate.  Double deprotonation of acid 88 and addition of the lithiated compound to 
a northern fragment aldehyde allowed access to a unit containing all skeletal carbon atoms.   
 
Scheme 3.14: Williams’ Approach to Southern Fragment Acid 88 
Barrett synthesized a similar southern fragment as Williams, but prepared it through 
modified Danishefsky Diels-Alder chemistry55 utilizing ethyl 2-pentynoate (89) and modified 
Danishefsky diene 90 (Scheme 3.16).  Smith’s southern fragment was synthesized by 
Barrett55 through Diels-Alder chemistry by reacting diene 90 with alkenoate 93 followed by 
alkaline workup to induce aromatization.  Kocienski also utilized this method in preparation 
of a southern fragment sulfone.57 
 
Scheme 3.15: Barrett's Approach to Southern Fragment Acid 92 and Ketone 94 
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Marko approaches the fragment coupling by synthesizing a more complex northern 
fragment mimic 97.  The vinyl borane 95 is utilized in a thallium carbonate–mediated Suzuki 
coupling85 with aryl iodide 96.  The fragment is not carried on to completion of the natural 
product, but provides an interesting alternative to classical incorporation of the southern 
fragment. 
 
Scheme 3.16: Marko's Approach to Southern Fragment 97 
Initial attempts at synthesis of the southern fragment 38 targeted a hydroxy 
acetophenone derivative 42 in a similar route parallel to Smith’s (Scheme 3.17).54  Mixed 
anhydride 98 was prepared from the corresponding protected hydroxy acid and pivaloyl 
chloride.  Inverse addition of the lithiated anisic acid derivative curiously resulted only in 
formation of trimethylacetophenone derivative (Table 3.7, Entry 1).  This product likely 
arises from attack of the lithiated aryl ring on excess pivaloyl chloride rather than attack of 
the lithiated aryl ring on the undesired side of the anhydride.  To attempt to utilize the facile 
addition into acid chlorides, the acid chloride of the protected hydroxy acid was prepared and 
used as an electrophile in the reaction (Entries 2, 3).  Regardless of the method of acid 
chloride formation, only recovered starting material or decomposition products were isolated.  
Additionally, the symmetric anhydride prepared from the protected hydroxy acid was used in 
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the reaction (Entry 4) and resulted only in recovered starting material and decomposition 
products. 
 
Scheme 3.17: General Strategy for Initial Attempts to Synthesize the Southern Fragment 
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Table 3.7: Anhydride and Acid Chloride Electrophiles 
 
Control reactions were carried out combining the lithiated aryl ring and pivaloyl 
chloride (Table 3.8, Entry 1).  A small amount of product was formed along with recovered 
starting material.  Attempts to react the lithiated aryl ring with acetyl chloride (Entry 2) led to 
decomposition and recovery of starting material.  Additional control reactions were carried 
out to ensure successful initial deprotonation.  Deprotonation followed by addition of 
deuterium oxide (Entry 3) or methyl iodide (Entry 4) both provided appreciable amounts of 
deuterated and methylated product, proving successful deprotonation. 
Control reactions were also carried out utilizing the procedure outlined by Smith.54  
Lithiation of either the aryl ring or a model aryl ring with t-butyllithium, s-butyllithium, or n-
butyllithium and reaction with acetic anhydride provided isolable quantities of the desired 
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aryl methyl ketone; however, never in more than 36% yield (Table 3.8, Entry 5-7).  Presence 
of the methyl ketone product during the course of the reaction likely serves to act as an acidic 
proton source to quench the lithiated aryl ring and prevent further product formation.  This is 
likely the reason why many of the electrophiles fail to yield appreciable product.  The enolate 
thus formed can also engage in deleterious reactions leading to decomposition products.  
While these reactions with acetic anhydride were control experiments, the products could 
plausibly be converted to the desired key intermediate.  Alpha hydroxylation of the methyl 
ketone would provide the requisite oxygenation needed on the route to the southern fragment.  
With the limited methyl ketone in hand, a number of Rubottom oxidation transformations 
were attempted.  On an acetophenone model system 101, successful Rubottom oxidation was 
achieved (Scheme 3.18).  Rubottom oxidation attempts with methyl ketone 82, however, 
produced no product, and only decomposition products were isolated. 
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Table 3.8: Control Reactions with Various Electrophiles 
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Scheme 3.18: Rubottom Oxidation Attempts 
Aldehydes were tested as possible electrophiles.  Propionaldehdye was tested as a 
simple test aldehyde.  Deprotonation with s-butyllithium and addition of propionaldehyde 
resulted in the secondary alcohol in 60% yield (Table 3.9, Entry 1).  However, when the 
protected hydroxy aldehyde was used, only recovered starting materials and decomposition 
products were isolated (Entries 2-3).  Neither addition of the lithiated aryl ring to the 
aldehyde nor addition of aldehyde to the lithiated aryl ring provided product.  Deprotonation 
with t-butyllithium or n-butyllithium also failed to provide product (Entries 4-5).  
Interestingly, one experiment where the aryl ring was deprotonated with n-butyllithium 
(Entry 5) provided reduced monoprotected ethanediol along with starting material and 
decomposition as the isolated products. 
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Table 3.9: Aldehyde Electrophiles 
 
Alternate methods of accessing the key phosphine oxide were considered.  Instead of 
adding vinyl Grignard to a protected α-hydroxy ketone, addition of a Grignard prepared from 
benzyloxymethyl chloride to an aryl vinyl ketone, 105, can access the same intermediate 
(Scheme 3.19).  Thus, oxidation of a secondary benzylic/allylic alcohol, 104, can further the 
synthesis of the southern fragment.  Moderate success was achieved utilizing a model aryl 
ring and acrolein as an electrophile.  Ortho-lithiation of oxazoline-protected benzoic acid and 
addition of acrolein resulted in inconsistent yields, but in the best case provided no more than 
20% product formation (Table 3.10, Entry 1).  Oxidation of the model benzylic alcohol 107 
with Dess-Martin periodinane resulted in decomposition (Scheme 3.20).  Interestingly, 
oxidation with manganese dioxide resulted in no oxidation, but rather isomerization of the 
allylic alcohol to the corresponding ethyl ketone 108.    Unfortunately, when the synthetically 
viable aryl ring was deprotonated (Table 3.10, Entries 2-3), exposure to acrolein – either by 
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direct addition of the lithiated aryl ring to acrolein or addition of acrolein to the lithiated aryl 
ring – only resulted in recovered starting material or decomposition products.  Even though 
limited success was achieved with the model system, no product was obtained upon reaction 
of the synthetically viable aryl ring. 
 
Scheme 3.19: Alternative Grignard Route to the Southern Fragment 
Table 3.10: Acrolein Electrophile Attempts 
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Scheme 3.20: Benzylic Alcohol Oxidation Attempts 
A key intermediate in the synthesis of the southern fragment is a tertiary benzylic 
alcohol.  Initial retrosynthesis sought an aryl ketone to which a Grignard reagent could be 
added.  If the lithiated aryl ring were added to a suitably functionalized ketone, the need to 
prepare and react an aryl ketone could be circumvented.  To that end, reaction of the lithiated 
model aryl ring 109 with methyl vinyl ketone (110) as a model ketone was tested (Scheme 
3.21).  Unfortunately, reaction of the lithiated model aryl ring with methyl vinyl ketone 
resulted in recovery of starting material.  Addition of cerium to modulate the nucleophilicity 
and basicity of the aryl ring failed to provide product. 
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Scheme 3.21: Methyl Vinyl Ketone as Electrophile Attempts 
Metal-catalyzed cross coupling reactions were also attempted in an effort to prepare 
the southern fragment.  Negishi conditions are known to facilitate the coupling of organozinc 
reagents and acid chlorides under palladium catalysis.86  Lithiation of the aryl ring followed 
by addition of zinc chloride formed the aryl zinc reagent needed for the Negishi coupling.  
Addition of palladium tetrakis(triphenylphosphine) and either benzoyl chloride as a model 
substrate or the protected hydroxy acid chloride only resulted in recovery of starting material 
in both cases (Table 3.11, Entries 1-3).  Negishi reaction with acetyl chloride (Entry 4) did 
provide product; however, reaction yields were inconsistent.  Approximately half of the 
Negishi reaction attempts using acetyl chloride provided limited amounts of aryl methyl 
ketone product and half only led to recovered starting material – and all reactions led to 
significant amounts of decomposition products.  These methyl ketones were used in some of 
the α-hydroxylation reactions described previously, and failed to be converted to useful 
intermediates. 
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Table 3.11: Negishi Cross Coupling Attempts 
 
Quenching of the lithiated aryl ring 81 with molecular iodine provided 13% of the 
aryl iodide 111 (Scheme 3.22) to be used in a Nozaki-Hiyama-Kishi coupling87 with the 
protected hydroxy aldehyde 112. Reaction of the aryl iodide 111 and aldehyde 112 under 
nickel/chromium catalysis failed to yield observable amounts of product formation. 
 
Scheme 3.22: Preparation of Aryl Iodide 111 and NHK Reaction Attempt 
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Gratifyingly, reaction of the model lithiated aryl ring 81 with trimethyl tin chloride 
provided stannylated product 113 in 57% yield (Scheme 3.23).  Stille coupling88 of the aryl 
tin with acryloyl chloride catalyzed by benzyl(chloro)bis(triphenylphosphine)palladium 
resulted in clean reaction; however, no desired product 114 was formed (Table 3.12, Entry 
1).  One product was protodestannylated aryl ring 115 where the oxazoline protecting group 
has been reduced and cleaved to the secondary amino alcohol.  A second product whose 
structure has not been unambiguously confirmed retains the tin, but with only two methyl 
groups attached.   
 
Scheme 3.23: Preparation of Aryl Tin 113 
The carbonylative Stille cross coupling reaction88 was also attempted.  The aryl tin 
reagent was reacted with vinyl bromide and tetrakis(triphenylphosphine)palladium under an 
atmosphere of carbon monoxide.  The reaction was attempted at 1 atmosphere carbon 
monoxide as well as 3 atmospheres of carbon monoxide (Table 3.12, Entries 2–4).  
Additionally, some of the reactions were carried out with copper(I) chloride as an additive.89  
When the reaction did not result in decomposition, the only isolated products were recovered 
starting material 113 or protodestannylated starting material 109. 
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Table 3.12: NHK and Stille Cross Coupling Attempts 
 
Finally, attempts to synthesize the southern fragment through a Diels-Alder strategy 
similar to the Barrett procedures were carried out.  (R)-But-3-ene-1,2-diol (116) was 
monoprotected90 and oxidized to the highly light sensitive enones 117 and 120 (Scheme 
3.24).  Addition of lithiated ethyl propynoate provided the corresponding tertiary alcohols 
which were protected as trimethylsilyl ethers 119 and 121 to provide the dienophile needed 
for the Diels-Alder reaction.  Attempts at preparation of modified Danishefsky’s diene 90 
proved problematic as literature precedent provided scant experimental details.91–94  Methyl 
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ethyl ketone was deprotonated with sodium hydride and reacted with methyl formate in a 
Claisen condensation reaction.  The resulting β-keto aldehyde was deprotonated with the 
methoxide byproduct to form an intermediate enolate.  The enolate is O-alkylated with 
methyl sulfate to give enone 123 in one pot.  Column chromatography of the enone required 
careful deactivation of the silica gel to avoid decomposition of enone product; however, 
significant byproduct formation proved inevitable.  Low yields of clean enone could be 
isolated, but reaction yields proved inconsistent.  Silyl enol ether formation also proved 
difficult.  Reaction of crude modified Danishefsky’s diene 90 with the dienophiles 119 or 
121 in refluxing xylenes followed by cyclization under acidic conditions resulted in 
decomposition products (Table 3.13, Entries 1-2).  Commercially available Danishefsky’s 
diene precursor was converted cleanly to Danishefsky’s diene95 and reacted with the 
dienophiles.  Diels-Alder reaction and acidic cyclization resulted only in recovery of 
deprotected dienophile (Entries 3-4). 
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Scheme 3.24:  Preparation of Dienophiles 119 and 121 and Diene 90 
 74 
 
Table 3.13: Diels-Alder Cyclization Attempts 
 
To this point, all attempts to form the southern fragment have been met with various 
levels of success; however, the completed southern fragment has eluded synthesis.  Work 
will continue on formation of the key isobenzofuranone needed to complete the southern 
fragment and ultimately milbemycin β14. 
C. Future Work 
Once isobenzofuranone 41 is successfully synthesized, preparation of phosphine 
oxide 38 utilizing Smith’s precedent54 will complete the synthesis of the southern fragment.  
To that end, SN2′ addition of lithiated diphenylphosphine followed by autoxidation and 
methylation with diazomethane will give methyl ester 38 and complete the southern fragment 
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(Scheme 3.25).  The southern and northern fragments will be coupled through an olefination 
reaction between the anion of phosphine oxide 38 and aldehyde 80.  Saponification of the 
methyl ester and deprotection of the protected secondary alcohol will yield hydroxy acid 125.  
Completion of the 16-member macrolactone and global deprotection will provide the natural 
product.  The northern fragment has been prepared in 13 steps and the southern fragment is 
proposed to be completed in 5 steps.  Coupling of the northern and southern fragment 
followed by four steps to complete the synthesis will result in the synthesis of milbemycin 
β14 in 18 overall longest linear steps. 
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Scheme 3.25: Proposed Synthetic Route for Completion of Milbemycin β14 
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CHAPTER 4 
4.EXPERIMENTAL DETAILS AND NMR 
 Materials and Methods: Infrared (IR) spectra were obtained using a JASCO FT/IR 
460-plus infrared spectrometer and values reported in cm-1.  Proton and carbon nuclear 
magnetic resonance (1H and 13C NMR) spectra were recorded on the following instruments: 
Bruker 300 (1H at 300 MHz), Bruker 400 (1H at 400 MHz; 13C at 100 MHz), and Bruker 500 
(1H at 500 MHz; 13C at 125 MHz).  Chemical shifts are reported in ppm with residual 
undeuterated solvent peaks as internal reference for 1H NMR: CHCl3 (7.24), CD2Cl2 (5.30) 
and for 13C NMR: CHCl3 (77.0), CD2Cl2 (53.8).  Coupling constants (J) are given in Hz.  
Optical rotations were determined using a JASCO P1010 polarimeter.  Thin layer 
chromatography (TLC) was conducted on silica gel F254 TLC plates purchased from Sorbent 
Technologies, Inc.  Flash chromatography was carried out using silica gel (32 to 63 μm) 
purchased from Sorbent Technologies, Inc.  Diethyl Ether (Et2O), tetrahydrofuran (THF), 
dichloromethane (CH2Cl2), and toluene (PhCH3) were dried by passing through a column of 
neutral alumina under nitrogen immediately prior to use.  Alkyl amines and 
hexamethylphosphoramide were distilled from calcium hydride immediately prior to use.  
Anhydrous N,N-dimethylformamide (DMF) was purchased from Aldrich chemical company 
in 1L Sure/SealTM bottles.  Volatile aldehydes were distilled neat immediately prior to use.  
Methyl iodide was distilled from calcium chloride immediately prior to use.  All other 
reagents and solvents were used as received from the manufacturer.  All air and water 
 83 
 
sensitive reactions were performed in flasks flame dried under a positive flow of argon and 
conducted under an argon atmosphere. 
 
Aldol Adduct 16: Preparation of (2S,3S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3-
(4-bromophenyl)-3-hydroxy-2-methylpropan-1-one 16.  A 1 L flame-dried round bottomed 
flask under argon was charged with (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)propan-1-one 
13 (15.292 g, 57.621 mmol) in dichloromethane (400 mL) at 0 °C.  Titanium(IV) chloride 
(6.7 mL, 60.502 mmol) was added and the reaction mixture was stirred at 0 °C for 5 min.    
(–)-Sparteine (13.1 mL, 57.621 mmol) was added and the reaction mixture was stirred at 0 
°C for 20 min.  The reaction mixture was cooled to -78 °C.  N-methylpyrrolidinone (5.5 mL, 
57.621 mmol) was added and the reaction mixture was stirred at -78 °C for 10 min.  4-
Bromobenzaldehyde 15 (11.727 g, 63.383 mmol) was dissolved in 60 mL CH2Cl2 and 
cannulated into the reaction mixture.  The reaction mixture was stirred for 1 h at -78 °C, and 
then the reaction mixture was allowed to warm slowly to 0 °C.  When the reaction was 
complete by TLC, the reaction was quenched with 1/2 saturated NH4Cl and warmed to room 
temperature.  The layers were separated and the aqueous layer was extracted 2x with CH2Cl2.  
The combined organic extracts were washed with brine, dried over Na2SO4, filtered and 
concentrated.  The product was purified by column chromatography (eluting with 15% 
EtOAc:hex) to yield the title compound as a yellow foam: 22.588 g, 50.150 mmol, 87% of 
the major diastereomer.  1H NMR (400 MHz, CDCl3): δ 7.21-7.45 (m, 9H), 4.95 (ddd, J = 
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3.6, 6.8, 10.4 Hz, 1H), 4.90, (d, J = 5.6 Hz, 1H), 4.75 (pentet, J = 6.8 Hz, 1H), 3.14 (dd, J = 
4.0, 13.2 Hz, 1H), 2.92-2.97 (m, 2H),  2.83 (br s, 1H), 2.78 (d, J = 11.6 Hz, 1H), 1.25 (d, J = 
6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 201.3, 177.1, 140.6, 136.2, 131.4, 131.3, 129.4, 
128.9, 128.0, 127.8, 127.3, 121.7, 74.9, 68.7, 46.1, 36.7, 32.2, 11.8; IR (film): 3462 (br), 
3085, 3062, 3029, 2979, 2934, 2874, 2360, 2338, 1691, 1342, 1263, 1165; MS (ESI): 
calculated for C20H20BrNO2S2 [M+Na]+: 472.0, found 472.1; [α] 23D  = +136.73 (c 0.70, 
CH2Cl2). 
 
Protected Aldol Adduct S1: Preparation of (2S,3S)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-3-(4-bromophenyl)-2-methyl-3-((triethylsilyl)oxy)propan-1-one S1.  
A flame-dried, 500 mL round bottom flask under argon was charged with (2S,3S)-1-((S)-4-
benzyl-2-thioxothiazolidin-3-yl)-3-(4-bromophenyl)-3-hydroxy-2-methylpropan-1-one 16 
(22.588 g, 50.150 mmol) in dichloromethane (330 mL) at -78 °C.  2,6-Lutidine (11.6 mL, 
100.300 mmol) was added followed by triethylsilyl trifluoromethanesulfonate (14.7 mL, 
65.195 mmol), and the reaction mixture was allowed to warm while stirring.  When the 
reaction was complete by TLC, the reaction was quenched with sat'd aq NaHCO3.  The layers 
were separated, and the aqueous layer was extracted 2x with CH2Cl2.  The combined organic 
layers were dried over Na2SO4, filtered and concentrated.  The product was purified by 
column chromatography (1 - 5% EtOAc: hex) to yield: 27.380 g, 48.489 mmol, 96.7%.  1H 
NMR (300 MHz, CDCl3): δ 7.17-7.40 (m, 9H), 4.60-4.49 (m, 2H), 4.45 (ddd, J = 4.2, 6.6, 
 85 
 
10.5 Hz, 1H), 3.09 (dd, J = 3.9, 13.5 Hz, 1H), 2.85 (dd, J = 10.8, 13.2 Hz, 1H), 2.62 (d, J = 
11.4 Hz, 1H), 2.45 (dd, J = 6.9, 11.1 Hz, 1H), 1.36 (d, J = 5.7 Hz, 3H), 0.82 (t, J = 7.8 Hz, 
9H), 0.45 (dq, J = 1.8, 7.5 Hz, 6H);  13C NMR (100 MHz, CDCl3): δ 201.1, 176.3, 142.4, 
136.5, 131.2, 129.4, 128.9, 128.5, 127.2, 121.6, 76.7, 69.0, 48.8, 36.6, 32.2, 14.0, 6.6, 4.8; IR 
(film): 3085, 3062, 3026, 2955, 2910, 2876, 1692, 1264, 1163, 1084, 839, 741; MS (ESI): 
calculated for C26H34BrNO2S2Si [M+Na]+: 586.1, found 586.1; [α] 23D  = +150.32 (c 1.05, 
CH2Cl2). 
 
Aldehyde 17: Preparation of (2S,3S)-3-(4-bromophenyl)-2-methyl-3-
((triethylsilyl)oxy)propanal 17.  A flame-dried 250 mL round bottom flask filled with argon 
was charged with (2S,3S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3-(4-bromophenyl)-2-
methyl-3-((triethylsilyl)oxy)propan-1-one S1 (10.100 g, 17.887 mmol) in dichloromethane 
(175 mL) at -78 °C.  Diisobutylaluminum hydride (1.0 M in hexane) (35.8 mL, 35.773 
mmol) was added dropwise.  The yellow color instantly faded to a clear colorless solution.  
The reaction was done immediately as monitored by TLC.  The reaction was quenched with 
saturated aqueous Rochelle's salt and diluted with Et2O.  The biphasic mixture was stirred 
vigorously for at least 1 h.  The layers were separated and the aqueous layer was extracted 2x 
Et2O.  The combined organic extracts were dried over Na2SO4, filtered and concentrated.  
The product was purified by column chromatography (dry load, eluting with 10-30% 
EtOAc:hex) to yield: 5.880 g, 16.455 mmol, 92%. The free auxiliary was recovered in 92.7% 
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yield. 1H NMR (400 MHz, CDCl3): δ 9.73 (d, J = 1.2 Hz, 1 H), 7.43 (d, J = 8.4 Hz, 2 H), 
7.16 (d, J = 8.4 Hz, 2 H), 5.11 (d, J = 4.0 Hz, 1 H), 2.53 (ddq, J = 1.2, 4.4, 6.8 Hz, 1 H), 1.00 
(d, J = 6.8 Hz, 3 H), 0.84 (t, J = 8.0 Hz, 9 H), 0.49 (q, J = 7.6 Hz, 6 H); 13C NMR (100 MHz, 
CDCl3): δ 203.8, 141.6, 131.3, 127.9, 121.3, 73.6, 54.5, 8.0, 6.7, 4.7; IR (film): 2955, 2911, 
2876, 2814, 2713, 1728, 1591, 1487, 1240, 1010, 743, 727; MS (ESI): calculated for 
C16H25BrO2Si [M+Na]+: 379.1, found 379.1; [α] 24D  = -27.01 (c 1.00, CH2Cl2).  
 
Unsaturated Ester S2: Preparation of (4R,5S,E)-ethyl 5-(4-bromophenyl)-4-methyl-
5-((triethylsilyl)oxy)pent-2-enoate S2.  A flame-dried 250 mL round bottom flask under 
argon was charged with (2S,3S)-3-(4-bromophenyl)-2-methyl-3-((triethylsilyl)oxy)propanal 
17 (3.543 g, 9.914 mmol) in THF (100 mL) at room temperature.  Ethyl 2-
(triphenylphosphoranylidene)acetate 18 (5.180 g, 14.870 mmol) was added in one portion.  
The reaction mixture was refluxed overnight.  The solvent was removed and the product was 
purified by column chromatography (dry load, eluting with 15% EtOAc:hex) to yield: 3.910 
g, 9.1463 mmol, 92.3%.  1H NMR (300 MHz, CDCl3): δ 7.40 (d, J = 8.4 Hz, 2H), 7.10 (d, J 
= 8.4 Hz, 2H), 6.89 (dd, J = 7.5, 15.9 Hz, 1H), 5.67 (dd, J = 0.9, 15.6 Hz, 1H), 4.55 (d, J = 
5.4 Hz, 1H), 4.14 (q, J = 6.8 Hz, 2H), 2.53 (sextet, J = 6.6, 1H), 1.25 (t, J = 7.2 Hz, 3H), 0.97 
(d, J = 6.9 Hz, 3H), 0.84 (t, J = 7.8 Hz, 9H), 0.47 (q, J = 7.8 Hz, 6H);  13C NMR (100 MHz, 
CDCl3): δ 166.4, 150.5, 142.0, 131.0, 128.2, 121.5, 121.0, 76.7, 60.1, 45.0, 14.2, 13.8, 6.7, 
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4.7; IR (film): 2956, 2938, 2910, 2876, 1903, 1720, 1654, 1180, 843; MS (ESI): calculated 
for C20H31BrO3Si [M+Na]+: 449.1, found 449.2; [α] 23D  = -14.21 (c 2.75, CH2Cl2). 
 
Saturated Ester 14: Preparation of (4R,5S)-ethyl 5-(4-bromophenyl)-4-methyl-5-
((triethylsilyl)oxy)pentanoate 14.  A flame-dried 3-neck 300-mL round bottom flask fitted 
with a reflux condenser under argon was charged with (4R,5S,E)-ethyl 5-(4-bromophenyl)-4-
methyl-5-((triethylsilyl)oxy)pent-2-enoate S2 (3.910 g, 9.146 mmol) in dimethoxyethane 
(100 mL).  p-Toluenesulfonyl hydrazide (11.923 g, 64.024 mmol) was added in one portion 
and the reaction mixture was brought to reflux.  Sodium acetate (7.503 g, 91.463 mmol) 
dissolved in water (65 mL) was added via syringe pump over 1 h.  The reaction was stirred at 
reflux for 4 h.  The reaction mixture was cooled and diluted with water and dichloromethane.  
The layers were separated and the aqueous layer was extracted 2x CH2Cl2.  The combined 
organic layers were washed with brine, dried over Na2SO4, filtered and concentrated.  The 
product was purified by column chromatography (dry load, eluting with 5% EtOAc:hex) to 
yield: 3.499 g, 8.1474 mmol, 89.1%.  1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 8.4, 2H), 
7.12 (d, J = 8.5, 2H), 4.45 (d, J = 4.9, 1H), 4.08 (q, J = 7.1, 2H), 2.28-2.36 (m, 1H), 2.16-
2.24 (m, 1H), 1.60-1.73 (m, 2H), 1.27-1.37 (m, 1H), 1.21 (t, J = 6.7, 3H), 0.84 (t, J = 8.1, 
9H), 0.81 (d, J = 6.8, 3H), 0.47 (q, J = 8.1, 6H); 13C (100 MHz, CDCl3) δ 173.6, 143.1, 
130.9, 128.3, 120.6, 77.9, 60.2, 31.0, 32.4, 28.2, 14.2, 14.0, 6.8, 4.8; IR (film): 2957, 2938, 
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2911, 2876, 1737, 1591, 1486, 1010, 844; MS (ESI): calculated for C20H33BrO3Si [M+Na]+: 
451.1, found 451.2; [α] 24D  = -31.85 (c 1.75, CH2Cl2). 
 
β-Keto Phosphonate 11: Preparation of dimethyl ((5R,6S)-6-(4-bromophenyl)-5-
methyl-2-oxo-6-((triethylsilyl)oxy)hexyl)phosphonate 11.  A 250 mL 3-necked flame-dried 
round bottom flask fitted with a jacketed addition funnel and internal thermometer under 
argon was charged with dimethyl methylphosphonate 19 (2.7 mL, 24.717 mmol) in THF (50 
mL) at -78 °C.  n-Butyllithium (1.6 M in hexanes) (15.3 mL, 24.470 mmol) was cooled to -
78 °C in the jacketed addition funnel and added dropwise to maintain internal temperature.  
The reaction mixture was stirred for 1 h.  (4R,5S)-ethyl 5-(4-bromophenyl)-4-methyl-5-
((triethylsilyl)oxy)pentanoate 14 (2.123 g, 4.943 mmol) was cooled to -78 °C in the jacketed 
addition funnel and added dropwise to maintain internal temperature.  The reaction was 
complete instantaneously as monitored by TLC.  The reaction was quenched with saturated 
aqueous NH4Cl.  The layers were separated and the aqueous layer was extracted 2x with 
Et2O.  The combined organic layers were dried over MgSO4, filtered and concentrated.  The 
product was purified by column chromatography (eluting with 75% EtOAc:hex) to yield: 
2.458 g, 4.844 mmol, 98%.  1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 8.4 Hz, 2H), 7.12 (d, 
J = 8.4 Hz, 2H), 4.43 (d, J = 4.8 Hz, 1H), 3.76 (s, 3H), 3.73 (s, 3H), 3.02 (d, J = 22.7 Hz, 
2H), 2.59-2.67 (m, 1H), 2.47-2.55 (m, 1H), 1.56-1.69 (m, 2H), 1.22-1.30 (m, 1H), 0.84 (t, J = 
8 Hz, 9H), 0.80 (d, J = 6.7 Hz, 3H), 0.47 (q, J = 7.8 Hz, 6H);  13C NMR (100 MHz, CDCl3): 
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δ 201.6, 143.0, 130.9, 128.4, 120.6, 78.0, 52.9, 42.1, 41.9, 40.8, 40.6, 26.5, 14.2, 6.7, 4.8; IR 
(film): 3460 (br), 2955, 2912, 2873, 2360, 2337, 1716, 1257, 1034, 843; MS (ESI): 
calculated for C21H36BrO5PSi [M+Na]+: 529.1, found 529.2; [α] 24D  = -25.49 (c 1.70, CH2Cl2). 
 
Aldol Adduct 21: Preparation of (2S,3R)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-3-
hydroxy-2-methylhex-5-en-1-one 21.  A 1-L flame-dried round bottom flask under argon was 
charged with (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)propan-1-one 13 (9.493 g, 35.770 
mmol) in CH2Cl2 (300 mL) at 0 °C.  Titanium(IV) chloride (4.1 mL, 37.558 mmol) was 
added and the reaction mixture was stirred for 5 min at 0 °C.  (–)-Sparteine (8.14 mL, 35.770 
mmol) was added and the reaction mixture was stirred for 20 min at 0 °C.  The reaction 
mixture was cooled to -78 °C.  N-methylpyrrolidinone (3.4 mL, 35.770 mmol) was added 
and the reaction mixture was stirred for 10 min at -78 °C.  But-3-enal 21 (1.3 M in CH2Cl2) 
(80 mL, 107.310 mmol) was cooled to -78 °C and cannulated into the reaction mixture.  The 
reaction mixture was stirred for 1 h at -78 °C and warmed gradually to 0 °C.  When the 
reaction was complete by TLC, the reaction was quenched with half saturated NH4Cl and 
warmed to room temperature.  The layers were separated and the aqueous layer was extracted 
2x with CH2Cl2.  The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated.  The product was purified by column chromatography (eluting with 
10-40% EtOAc:hex) to yield: 11.004 g, 32.8008 mmol, 91.7% of the major diastereomer.  1H 
NMR (300 MHz, CDCl3): δ 7.28-7.34 (m, 5H), 5.71-5.85 (m, 1H), 5.29-5.36 (m, 1H) 5.14 (d, 
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J = 5.7 Hz, 1H), 5.091 (s, 1H), 4.46-4.50 (m, 1H), 3.98-4.01 (m, 1H), 3.38 (dd, J = 6.6, 11.4 
Hz, 1H), 3.20 (dd, J = 3.9, 13.2 Hz, 1H), 3.02 (dd, J = 10.5, 12.9 Hz, 1H), 2.88 (d, J = 11.4 
Hz, 1H), 2.62 (d, J = 3.0 Hz, 1H), 2.18-2.31 (m, 2H), 1.26 (d, J = 6.9 Hz, 3H);  13C NMR 
(100 MHz, CDCl3): δ 201.2, 177.9, 136.3, 134.2, 129.4, 128.9, 127.3, 118.1, 71.6, 68.7, 42.8, 
38.9, 36.8, 32.1, 10.8; IR (film): 3448 (br), 3064, 3027, 2978, 2937, 1689, 1341, 1261, 1165, 
1029, 702;  MS (ESI): calculated for C17H21NO2S2 [M+Na]+: 358.1, found 358.1; [α] 23D  = 
+168.13 (c 1.15, CH2Cl2). 
 
Protected Aldol Adduct S3: Preparation of (2S,3R)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-2-methyl-3-((triethylsilyl)oxy)hex-5-en-1-one.  A 300 mL flame-
dried round bottom flask under argon is charged with (2S,3R)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-3-hydroxy-2-methylhex-5-en-1-one 21 (6.505 g, 19.391 mmol) in 
dichloromethane (130 mL) at -78 °C.  2,6-Lutidine (6.7 mL, 58.174 mmol) was added 
followed by triethylsilyl trifluoromethanesulfonate (7.7 mL, 33.935 mmol) and the reaction 
was stirred while gradually warming to 0 °C.  When the reaction was complete by TLC, the 
reaction was quenched with saturated aqueous NaHCO3.  The layers were separated and the 
aqueous layer was extracted 2x with CH2Cl2.  The combined organic layers were dried over 
Na2SO4, filtered and concentrated.  The product was purified by column chromatography 
(eluting with 1 - 5% EtOAc:hex) to yield: 7.235 g, 16.087 mmol, 83%.  1H NMR (300 MHz, 
CDCl3): δ 7.30 (m, 5H), 5.80 (dddd, J = 7.2, 7.2, 10.5, 17.4 Hz, 1H), 5.18 (ddd, J = 3.9, 6.9, 
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10.5 Hz, 1H), 5.013 (m, 2H), 4.43 (pentet, J = 6.6 Hz, 1H), 4.09 (q, J = 5.7 Hz, 1H), 3.26 (m, 
2H), 3.01 (dd, J = 10.8, 12.9 Hz, 1H), 2.87 (d, J = 11.7, 1H), 2.26 (m, 2H), 1.23 (d, J = 6.9 
Hz, 3H), 0.93 (t, J = 8.1 Hz, 9H), 0.57 (q, J = 7.8 Hz, 6H);  13C NMR (100 MHz, CDCl3): δ 
200.7, 176.7, 136.7, 134.6, 129.5, 128.9, 127.2, 117.1, 73.8, 69.3, 44.5, 40.6, 36.7, 32.0, 13.1, 
6.9, 5.2; IR (film): 3065, 3028, 2954, 291, 2876, 1693, 1455, 1257, 913, 742; MS (ESI) 
calculated for C23H35NO2S2Si [M+Na]+: 472.2, found 472.3; [α] 23D  = +148.05 (c 1.55, 
CH2Cl2). 
 
Aldehyde 10: Preparation of (2S,3R)-2-methyl-3-((triethylsilyl)oxy)hex-5-enal 10.  A 
250-mL flame-dried round bottom flask under argon was charged with (2S,3R)-1-((S)-4-
benzyl-2-thioxothiazolidin-3-yl)-2-methyl-3-((triethylsilyl)oxy)hex-5-en-1-one S3 (4.745 g, 
10.549 mmol) in dichloromethane (100 mL) at -78 °C.  Diisobutylaluminum hydride (1.0 M 
in hexanes) (21.1 mL, 21.098 mmol) was added dropwise and the yellow reaction mixture 
immediately turned clear and colorless.  The reaction was quenched with Rochelle's salt and 
diluted with Et2O.  The layers were separated and the aqueous layer was extracted 2x with 
Et2O.  The combined organic layers were dried over Na2SO4, filtered and concentrated.  The 
product was purified by column chromatography (dry load, eluting with 5 - 30% EtOAc:hex) 
to yield: 1.869 g, 7.7099 mmol, 73.1%.  1H NMR (400 MHz, CDCl3): δ 9.73 (d, J = 0.8 Hz, 
1H), 5.73 (dddd, J = 7.2, 7.2, 10, 17.2 Hz, 1 H), 5.05-5.10 (m, 2H), 4.20 (dt, J = 3.6, 6.8 Hz, 
1 H), 2.43 (ddq, J = 0.8, 3.6, 7.2 Hz, 1 H), 2.28 (ddd, J = 1.2, 1.2, 7.2 Hz, 2 H), 1.07 (d, J = 
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6.8 Hz, 3 H), 0.92 (t, J = 8.4 Hz, 9 H), 0.57 (q, J = 7.8 Hz, 6 H); 13C NMR (100 MHz, 
CDCl3): δ 204.9, 134.2, 117.9, 71.5, 51.0, 39.7, 7.5, 6.8, 5.1; IR (film): 3079, 2956, 2913, 
2878, 2710, 1731, 1459, 1106, 742; MS (ESI): calculated for C13H26O2Si [M+Na]+: 265.2, 
found 265.2; [α] 25D  = +37.69 (c 0.75, CH2Cl2). 
 
Unsaturated Ketone S4: Preparation of (4R,5R,11R,12S,E)-4,12-
bis((triethylsilyl)oxy)-5,11-dimethyl-12-(4-bromophenyl)-1,6-dodecadiene-8-one S4.  A 100-
mL flame-dried round bottom flask under argon was charged with dimethyl ((5R,6S)-6-(4-
bromophenyl)-5-methyl-2-oxo-6-((triethylsilyl)oxy)hexyl)phosphonate 11 (4.037 g, 7.955 
mmol) in THF (20 mL) at room temperature.  Barium hydroxide (0.954 g, 5.568 mmol) was 
added in one portion and the suspension was stirred vigorously at room temperature for 30 
min.  (2S,3R)-2-methyl-3-((triethylsilyl)oxy)hex-5-enal 10 (6.629 mmol, as a 0.3 M solution 
in 40:1 THF:H2O (20.5 mL)) was added dropwise and the reaction mixture was stirred 
vigorously at room temperature.  When the reaction was complete by TLC, the reaction 
mixture was diluted with Et2O and filtered through Celite.  The filtrate was washed with 
saturated aqueous NaHCO3 and the aqueous layer was back extracted 2x with EtOAc (the 
aqueous layer was checked by TLC to ensure complete extraction of product).  The 
combined organic layers were dried over Na2SO4, filtered and concentrated.  The product 
was purified by column chromatography (eluting with 7% EtOAc:hex) to yield: 3.435 g, 
5.5055 mmol, 83.1%.  1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 
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8.5 Hz, 2H), 6.79 (dd, J = 7.4, 16.0 Hz, 1H), 6.00 (d, J = 16.1 Hz, 1H), 5.76 (m, 1H), 5.02 
(m, 2H), 4.45 (d, J = 4.9 Hz, 1H), 3.67 (q, J = 5.6 Hz, 1H), 2.55 (m, 1H), 2.42 (m, 2H), 2.21 
(m, 1H), 2.11 (m, 1H), 1.64 (m, 2H), 1.32 (m, 1H), 1.01 (d, J = 6.8 Hz, 3H), 0.93 (t, J = 8.0 
Hz, 9H), 0.84 (t, J = 8.0 Hz, 9H), 0.82 (d, J = 6.6 Hz, 3H), 0.57 (q, J = 7.8 Hz, 6H), 0.47 (q, J 
= 7.8 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 200.3, 149.5, 143.2, 134.8, 130.9, 129.8, 
128.4, 120.6, 117.2, 78.2, 74.9, 41.8, 41.2, 39.4, 38.1, 27.5, 14.2, 13.9, 6.9, 6.7, 5.2, 4.9; IR 
(film): 2956, 2911, 2876, 2360, 1698, 1676, 1628, 1486, 1459, 1072, 1010, 742; MS (ESI): 
calculated for C32H55BrO3Si2 [M+Na]+: 645.3, found 645.3;  [α] 25D  = -5.58 (c 0.95, CH2Cl2). 
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Saturated Ketone 22: Preparation (4R,5R,11R,12S)-4,12-bis((triethylsilyl)oxy)-5,11-
dimethyl-12-(4-bromophenyl)-1-dodecene-8-one 22.  A 300-mL flame-dried round bottom 
flask under argon was charged with copper(I) iodide (0.210 g, 1.101 mmol) in THF (55 mL) 
at -50 °C.  Methyllithium (0.7 mL, 1.101 mmol) was added followed by 
hexamethylphosphoramide (11.0 mL, 63.313 mmol) and diisobutylaluminum hydride (1.0 M 
in hexane) (14.3 mL, 14.314 mmol).  The reaction mixture was stirred for 30 min at -50 °C.  
(4R,5R,11R,12S,E)-4,12-bis((triethylsilyl)oxy)-5,11-dimethyl-12-(4-bromophenyl)-1,6-
dodecadiene-8-one S4 (3.435 g, 5.505 mmol) was added in THF (55 mL) and the reaction 
mixture was stirred for 1 h at -50 °C.  The reaction was followed by NMR of quenched 
aliquots as the starting material and product have the same Rf by TLC.  When the reaction 
was complete by NMR (monitoring the characteristic enone proton signals), the reaction was 
quenched with ice-cold 1M HCl and the layers were immediately separated to avoid silyl 
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ether deprotection.  The organic layer was washed 2x ice-cold 1M HCl and the layers were 
again separated immediately.  The combined organic layers were washed 3x with H2O and 
the combined aqueous layers were back extracted 3x with Et2O.  The combined organic 
layers were dried over MgSO4, filtered and concentrated.  The product was purified by 
column chromatography (eluting with 5% EtOAc:hex) to yield: 3.118 g, 4.9822 mmol, 
90.5%.  1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 
5.74 (m, 1H), 5.00 (m, 2H), 4.43 (d, J = 4.8, 1H), 3.57 (m, 1H), 2.34 (m, 4H), 2.18 (t, J = 6.7, 
2H), 1.63 (m, 3H), 1.45 (m, 1H), 1.31 (m, 2H), 0.94 (t, J = 8.1 Hz, 9H), 0.83 (m, 14H), 0.56 
(q, J = 7.7 Hz, 6H), 0.51 (q, J = 8.1 Hz, 6H);  13C NMR (100 MHz, CDCl3): δ 211.2, 143.1, 
135.6, 130.8, 128.3, 120.6, 116.6, 78.1, 75.5, 41.0, 41.0, 40.7, 38.8, 37.3, 27.0, 14.2, 13.9, 
7.0, 6.8, 5.2, 4.8; IR (film): 3077, 2956, 2912, 2876, 1715, 1459, 1414, 1380, 1239, 1072, 
1010, 741; MS (ESI): calculated for C32H57BrO3Si2 [M+Na]+: 647.3, found 647.3;  [α] 23D  =    
-12.97 (c 0.95, CH2Cl2). 
 
Dihydroxyketone 9: Preparation of (1S,2R,8R,9R)-1-(4-bromophenyl)-1,9-
dihydroxy-2,8-dimethyldodec-11-en-5-one 9.  A 100 mL flame-dried round bottom flask 
under argon was charged with (4R,5R,11R,12S)-4,12-bis((triethylsilyl)oxy)-5,11-dimethyl-
12-(4-bromophenyl)-1-dodecene-8-one 22 (2.948 g, 4.710 mmol) in THF (31 mL) at 0 °C.  
Tetrabutylammonium fluoride (1.0 M in THF) (37.7 mL, 37.678 mmol) was added and the 
reaction mixture was allowed to warm to room temperature.  When the reaction was 
complete by TLC, the reaction was quenched with saturated aqueous NaHCO3.  The layers 
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were separated and the product was extracted 2x with Et2O.  The combined organic layers 
were dried over MgSO4, filtered and concentrated.  The product was quickly purified by 
column chromatography (deactivated with NEt3, eluting with 50 - 75% EtOAc:hex) to yield: 
1.870 g, 4.7062 mmol, 99.9%.  Due to the extreme sensitivity of the diol, the product was 
carried directly to the next step. 
 
Spiroketal 8: Preparation of (2R,3R,6S,8S,9R)-2-allyl-8-(4-bromophenyl)-3,9-
dimethyl-1,7-dioxaspiro[5.5]undecane 8.  A 100 mL round bottom flask was charged with 
(1S,2R,8R,9R)-1-(4-bromophenyl)-1,9-dihydroxy-2,8-dimethyldodec-11-en-5-one 9 (1.870 g, 
4.706 mmol) in wet dichloromethane (50 mL) at room temperature.  PPTS (0.059 g, 0.235 
mmol) was added and the reaction mixture was stirred at room temperature.  The solvent was 
removed under reduced pressure and the product was directly purified by column 
chromatography (eluting with 2% Et2O:hex) to yield: 1.530 g, 4.0334 mmol, 85.7%.  1H 
NMR (400 MHz, CDCl3): δ 7.44 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 5.82 (dddd, J 
= 6.4, 7.7, 10.1, 16.8 Hz, 1H), 4.97-5.07 (m, 2H), 4.84 (d, J = 2.7 Hz, 1H), 3.64 (ddd, J = 2.4, 
5.5, 8.0 Hz, 1H), 2.12-2.31 (m, 3H), 1.92-2.05 (m, 2H), 1.38-1.72 (m, 7H), 0.93 (d, J = 6.9 
Hz, 3H), 0.65 (d, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) 141.6, 135.7, 130.9, 127.5, 
127.4, 120.0, 116.3, 96.8, 71.4, 71.0, 37.6, 32.2, 30.0, 29.8, 29.6, 26.5, 26.2, 10.9, 10.9; IR 
(film): 3076, 2936, 2894, 1642, 1489, 1380, 1233, 1070, 990, 785; HRMS (ESI): calculated 
for C20H27BrO2 [M+Na]+: 401.109, found 401.108; [α] 25D  = -30.87 (c 1.05, CH2Cl2). 
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Acylated Auxiliary 27: Preparation of (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)pent-
4-en-1-one 27.  A 250 mL flame-dried round bottom flask under argon was charged with (S)-
4-benzylthiazolidine-2-thione 25 (5.063 g, 24.223 mmol) in dichloromethane (120 mL) at 0 
°C.  Pent-4-enoic acid 26 (2.2 mL, 22.021 mmol) was added, followed sequentially by 
dicyclohexylcarbodiimide (4.544 g, 22.021 mmol) and dimethylamino pyridine (0.135 g, 
1.101 mmol) at 0 °C.  The reaction mixture was stirred at room temperature.  When the 
reaction was complete by TLC, the reaction mixture was cooled to 0 °C and filtered.  The 
filter cake was washed with dichloromethane and the filtrate was washed with saturated 
aqueous NaHCO3.  The aqueous layer was back extracted 2x with CH2Cl2.  The combined 
organic layers were dried over Na2SO4, filtered and concentrated.  The product was purified 
by column chromatography (eluting with 10% EtOAc:hex) to yield: 5.649 g, 19.384 mmol, 
88%.  1H NMR (300 MHz, CDCl3): δ 7.25-7.35 (m, 5H), 5.85 (dddd, J = 6.3, 6.3, 10.2, 16.8 
Hz, 1H), 4.99-5.10 (m, 2H), 3.47 (ddd, J = 6.3, 8.1, 17.7 Hz, 1H), 3.36 (dd, J = 7.5, 11.4 Hz, 
1H), 3.27 (dd, J = 6.9, 8.1 Hz, 1H), 3.17-3.23 (m, 1H), 3.02 (dd, J = 10.5, 12.9 Hz, 1H), 2.86 
(d, J = 11.7 Hz, 1H), 2.36-2.53 (m, 2H); 13C NMR (100 MHz, CDCl3): δ 201.1, 173.3, 136.7, 
136.5, 129.4, 128.9, 127.2, 115.6, 68.5, 37.8, 36.8, 31.9, 28.6; IR (film): 3078, 3029, 3003, 
2976, 2921, 1697, 1342, 1266, 1163, 702; MS (ESI): calculated for C15H17NOS2 [M+Na]+: 
314.1, found 314.0; [α] 24D  = +168.69 (c 0.75, CH2Cl2). 
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Aldol Adduct 28: Preparation of (S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-
((R)-1-hydroxyethyl)pent-4-en-1-one 28.  A 500-mL flame-dried round bottom flask under 
argon was charged with (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)pent-4-en-1-one 27 (6.014 
g, 20.636 mmol) in dichloromethane (175 mL) at 0 °C.  Titanium(IV) chloride (2.4 mL, 
21.668 mmol) was added and the reaction mixture was stirred at 0 °C for 5 min.  (–)-
Sparteine (4.7 mL, 20.636 mmol) was added and the reaction mixture was stirred at 0 °C for 
5 min.  The reaction mixture was cooled to -78 °C, N-methylpyrrolidinone (2.0 mL, 20.636 
mmol) was added, and the reaction mixture was stirred for 10 min at -78 °C.  Acetaldehyde 
(1.3 mL, 22.700 mmol from a previously unopened new bottle) was added and the reaction 
mixture was stirred at -78 °C for 1 h.  The reaction mixture was allowed to warm slowly to 0 
°C and the reaction was quenched with 1/2 saturated aqueous NH4Cl.  The layers were 
separated and the aqueous layer was extracted 2x with CH2Cl2.  The combined organic layers 
were dried over Na2SO4, filtered and concentrated.  The product was purified by column 
chromatography (eluting with 10-20% EtOAc:hex) to yield: 3.726 g, 11.1065 mmol, 53.8%.  
1H NMR (300 MHz, CDCl3): δ 7.25-7.35 (m, 5H), 5.91 (dddd, J = 6.9, 6.9, 10.2, 17.1 Hz, 
1H), 5.09-5.15 (m, 1H), 5.00-5.06 (m, 2H), 3.34 (dd, J = 7.2, 11.4 Hz, 1H), 3.17 (dd, J = 3.6, 
13.2 Hz, 1H), 3.00 (dd, J = 10.8, 13.2 Hz, 1H), 2.84 (d, J = 11.4 Hz, 1H), 2.60-2.70 (m, 1H), 
2.42-2.50 (m, 1H), 1.22 (d, J = 6.3 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 202.0, 175.6, 
136.4, 135.6, 129.4, 128.9, 127.2, 117.1, 69.0, 68.9, 48.9, 36.9, 31.7, 31.5, 20.3; IR (film): 
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3437 (br), 3068, 3026, 2976, 2926, 2858, 1691, 1259, 1164, 998; MS (ESI): calculated for 
C17H21NO2S2 [M+Na]+: 358.1, found 358.1; [α] 25D  = +177.14 (c 0.75, CH2Cl2). 
 
Protected Aldol Adduct S6: Preparation of (S)-1-((S)-4-benzyl-2-thioxothiazolidin-
3-yl)-2-((R)-1-((triethylsilyl)oxy)ethyl)pent-4-en-1-one S6.  A 250 mL flame-dried round 
bottom flask under argon was charged with (S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-
((R)-1-hydroxyethyl)pent-4-en-1-one 28 (3.932 g, 11.720 mmol) in dichloromethane (80 mL) 
at -78 °C.  2,6-Lutidine (2.7 mL, 23.439 mmol) was added followed by triethylsilyl 
trifluoromethanesulfonate (3.4 mL, 15.236 mmol) and the reaction mixture was allowed to 
warm to 0 °C while stirring.  When the reaction was complete by TLC, the reaction was 
quenched with saturated aqueous NaHCO3. The layers were separated and the aqueous layer 
was extracted 2x with CH2Cl2.  The combined organic layers were dried over Na2SO4, 
filtered and concentrated.  The product was purified by column chromatography (eluting with 
1-5% EtOAc:hex) to yield: 5.018 g, 11.1562 mmol, 95.2%.  1H NMR (400 MHz, CDCl3): δ 
7.24-7.34 (m, 5H), 5.74-5.84 (m, 1H), 5.21 (ddd, J = 3.6, 6.8, 10.4 Hz, 1H), 5.02 (d, J = 17.2 
Hz, 1H), 4.95 (d, J = 10 Hz, 1H), 4.85 (ddd, J = 4.8, 7.6, 10.4 Hz, 1H), 4.20 (pentet, J = 6.4 
Hz, 1H), 3.18-3.28 (m, 2H), 3.02 (dd, J = 10.8, 12.4 Hz, 1H), 2.82 (d, J = 11.2 Hz, 1H), 2.56-
2.62 (m, 1H), 2.35-2.43 (m, 1H), 1.26 (d, J = 6.2 Hz, 3H), 0.96 (t, J = 7.8 Hz, 9H), 0.60 (q, J 
= 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3): δ 201.4, 175.8, 136.6, 135.8, 129.4, 128.9, 
127.2, 116.4, 69.3, 69.1, 53.4, 50.7, 37.0, 34.8, 32.2, 22.3, 6.9, 5.2, 4.9; IR (film): 3064, 
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3026, 2954, 2911, 2872, 2359, 2336, 1694, 1260, 1164, 743; MS (ESI): calculated for 
C23H35NO2S2Si [M+Na]+: 472.2, found 472.3; [α] 25D  = +187.20 (c 1.05, CH2Cl2).  
 
Aldehyde 24: Preparation of (S)-2-((R)-1-((triethylsilyl)oxy)ethyl)pent-4-enal 24.  A 
100 mL flame dried round bottom flask under argon was charged with (S)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-2-((R)-1-((triethylsilyl)oxy)ethyl)pent-4-en-1-one S6 (2.249 g, 5.001 
mmol) in dichloromethane (50 mL) at -78 °C.  Diisobutylaluminum hydride (1.0 M in 
hexane) (10.0 mL, 10.001 mmol) was added and the color changed from bright yellow to 
colorless instantly.  The reaction was complete instantaneously by TLC, and the reaction was 
quenched with saturated aqueous Rochelle's salt and diluted with Et2O.  The biphasic mixture 
was stirred vigorously for at least 1 h.  The layers were separated and the aqueous layer was 
extracted 2x with Et2O.  The combined organic layers were dried over Na2SO4, filtered and 
concentrated.  The product was purified by column chromatography (eluting with 5-30% 
EtOAc:hex) to yield: 1.065 g, 4.3930 mmol, 87.9%.  1H NMR (500 MHz, CDCl3): δ 9.78 (d, 
J = 1.6 Hz, 1H), 5.74 (dddd, J = 5.2, 5.2, 8.0, 13.2 Hz, 1H), 5.06-5.00 (m, 2H), 4.12-4.14 (m, 
1H), 2.51-2.43 (m, 2H), 2.22-2.17 (m, 1H), 1.16 (d, J = 5.2 Hz, 3H), 0.93 (t, J = 6.4 Hz, 9H), 
0.58 (q, J = 6.4 Hz, 6H); 13C NMR (125MHz, CDCl3): 205.1, 135.7, 116.7, 67.8, 58.4, 29.1, 
21.1, 6.8, 4.9; IR (film): 3084, 2957, 2914, 2878, 2830, 2733, 1727, 1459, 1416, 1382, 1241, 
1009, 744; MS (ESI): calculated for C13H26O2Si [M+Na]+: 265.2, found 265.1; [α] 24D  =          
-37.40 (c 0.35, CH2Cl2). 
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Unsaturated Ketone S7: Preparation of (2R,3R,9R,10S,E)-2,10-
bis((triethylsilyl)oxy)-3-allyl-9-methyl-10-(4-bromophenyl)-4-decene-6-one S7.  A 100 mL 
flame dried round bottom flask under argon was charged with dimethyl ((5R,6S)-6-(4-
bromophenyl)-5-methyl-2-oxo-6-((triethylsilyl)oxy)hexyl)phosphonate 11 (2.675 g, 5.271 
mmol) in THF (13.178 mL) at rt.  Barium hydroxide (0.632 g, 3.690 mmol) was added and 
the reaction mixture was stirred vigorously for 30 min at rt.  (S)-2-((R)-1-
((triethylsilyl)oxy)ethyl)pent-4-enal 24 (1.065 g, 4.393 mmol) was added and the reaction 
mixture was stirred at rt.  When the reaction was complete by TLC, the reaction mixture was 
diluted with Et2O and filtered through Celite.  The filtrate was washed with NaHCO3 and the 
combined aqueous layers were back extracted with EtOAc.  The aqueous layer was checked 
by TLC to ensure complete extraction of product.  The combined organic layers were dried 
over Na2SO4, filtered and concentrated.  The product was purified by column 
chromatography (eluting with 7.5-75% EtOAc:hex) to yield: 1.937 g, 3.1049 mmol, 70.7%.  
1H NMR (400 MHz, CDCl3): δ 7.38 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 6.62 (dd, J 
= 8.8, 16.0 Hz, 1H), 5.99 (dd, J = 1.2, 16.0 Hz, 1H), 5.64 (dddd, J = 7.2, 10.4, 17.2 Hz, 1H), 
4.97 (m, 2H), 4.44 (d, J = 4.8 Hz, 1H), 3.79 (pentet, J = 6.0 Hz, 1H), 2.48 (m, 2H), 2.36 (m, 
1H), 2.25 (m, 1H), 2.08 (m, 1H), 1.63 (m, 2H), 1.31 (m, 1H), 1.06 (d, J = 6.4 Hz, 3H), 0.94 
(t, J = 8.0 Hz, 9H), 0.83 (m, 12H), 0.57 (q, J = 8.0 Hz, 6H), 0.47 (q, J = 7.9 Hz, 6H); 13C 
NMR (100 MHz, CDCl3): δ 200.3, 147.3, 143.2, 136.1, 131.4, 130.8, 128.3, 120.6, 116.5, 
78.1, 69.9, 50.4, 41.1, 38.0, 34.3, 27.5, 21.0, 14.2, 6.9, 6.8, 5.0, 4.8;  IR (film): 3078, 2956, 
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2912, 2876, 1697, 1675, 1631, 1460, 1414, 1379, 1239, 1072, 1010, 742; MS (ESI): 
calculated for C32H55BrO3Si2 [M+Na]+: 645.3, found 645.3;  [α] 23D  = -25.27 (c 1.45, CH2Cl2). 
 
Saturated Ketone 29: Preparation of (2R,3S,9R,10S)-3-allyl-2,10-
bis((triethylsilyl)oxy)-9-methyl-10-(4-bromophenyl)-decane-6-one 29.  A 250 mL flame-
dried round bottom flask under argon was charged with copper(I) iodide (0.118 g, 0.621 
mmol) in 31 mL THF at -50 °C.  Methyllithium (0.38 mL, 0.621 mmol), 
hexamethylphosphoramide (6.21 mL, 35.707 mmol) and diisobutylaluminum hydride (1.0 M 
in hexane) (8.07 mL, 8.073 mmol) were added sequentially and the reaction mixture was 
stirred for 30 min at -50 °C.  (2R,3R,9R,10S,E)-2,10-bis((triethylsilyl)oxy)-3-allyl-9-methyl-
10-(4-bromophenyl)-4-decene-6-one S7 (1.937 g, 3.105 mmol) was added in 31 mL THF and 
the reaction mixture was stirred for 1h at -50 °C.  The reaction was quenched with 1M ice-
cold HCl and the layers were separated immediately.  The organic layer was extracted 2x 1M 
ice-cold HCl and washed 3x with H2O.  The combined aqueous layers were back extracted 
3x with Et2O.  The combined organic layers were dried with MgSO4, filtered and 
concentrated.  The product was purified by column chromatography (eluting with 5% 
EtOAc:hex) to yield: 1.828 g, 2.9207 mmol, 94.1%.  1H NMR (400 MHz, CDCl3): 7.42 (d, J 
= 2.0 Hz, 2H), 7.18 (d, J = 1.6 Hz, 2H), 5.78 (dddd, J = 7.2, 10.4, 17.2 Hz, 1H), 4.99 (m, 
2H), 4.48 (d, J = 4.8 Hz, 1H), 3.83 (m, 1H), 2.40 (m, 3H), 2.29 (m, 1H), 2.01 (m, 2H), 1.62 
(m, 3H), 1.40 (m, 2H), 1.24 (m, 1H), 1.06 (d, J = 6.4 Hz, 3H), 0.94 (t, J = 8.0, 9H), 0.86 (t, J 
= 8.0, 9H), 0.57 (q, J = 8.0 Hz, 6H), 0.52 (q, J = 7.6 Hz, 6H); 13C NMR (100 MHz, CDCl3): 
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δ 211.0, 143.2, 137.6, 130.9, 128.4, 120.7, 115.7, 78.2, 69.8, 44.7, 41.2, 41.1, 40.7, 35.2, 
27.1, 23.6, 19.4, 14.2, 6.9, 6.7, 5.1, 4.9; IR (film): 3076, 2955, 2912, 2876, 1714, 1458, 1414, 
1379, 1239, 1071, 1010, 742; MS (ESI): calculated for C32H57BrO3Si2 [M+Na]+: 647.3, 
found 647.3; [α] 23D  = -19.67 (c 1.05, CH2Cl2). 
 
Spiroketal 23b Preparation of (2R,3S,6R,8S,9R)-3-allyl-8-(4-bromophenyl)-2,9-
dimethyl-1,7-dioxaspiro[5.5]undecane 23b.  A 1-dram vial was charged with 
(2R,3S,9R,10S)-3-allyl-2,10-bis((triethylsilyl)oxy)-9-methyl-10-(4-bromophenyl)-decane-6-
one 29 (0.100 g, 0.160 mmol) in acetonitrile (1.0 mL) at rt.  Hydrofluoric acid (49% in H2O, 
10 drops) was added slowly and the reaction mixture was stirred at rt.  The reaction mixture 
was quenched with saturated aqueous NaHCO3 and diluted with Et2O.  The layers were 
separated and the aqueous layer was extracted 2x with Et2O.  The combined organic layers 
were dried over MgSO4, filtered and concentrated.  The product was purified by column 
chromatography (eluting with 2% Et2O:hex) to yield: 0.049 g, 0.1292 mmol, 80.8 % as an 
inseparable 13:1 mixture of spiroketal diastereomers.  1H NMR (400 MHz, CD2Cl2): δ 7.44 
(d, J = 8.4 Hz, 2H), 7.21 (d, J = 8.6 Hz, 2H), 5.75 (dddd, J = 7.2, 7.2, 10.4, 17.2 Hz, 1H), 
5.10 (d, J = 2.8 Hz, 1H), 5.04-4.97 (m, 2H), 3.96-3.90 (m, 1H), 2.27-2.18 (m, 1H), 1.99-1.84 
(m, 4H), 1.83-1.72 (m, 2H), 1.67-1.48 (m, 5H), 1.06 (d, J = 6.8 Hz, 3H), 0.62 (d, J = 6.8 Hz, 
3H); 13C NMR (100 MHz, CD2Cl2): δ 142.3, 137.5, 131.2, 128.0, 120.2, 116.0, 97.1, 72.8, 
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72.5, 39.3, 36.8, 36.3, 33.0, 30.1, 26.8, 20.7, 15.4, 11.1; IR (film): 3078, 2935, 2866, 1640, 
1489, 1453, 1380, 1226, 1103, 996, 787; MS (ESI): calculated for C20H27BrO2 [M+Na]+: 
401.1, found 401.1. 
 
Dihydroxyketone S8: Preparation of (1S,2R,8S)-1-(4-bromophenyl)-1-hydroxy-8-
((R)-1-hydroxyethyl)-2-methylundec-10-en-5-one S8.  A flame dried vial under argon was 
charged with with (2R,3S,9R,10S)-3-allyl-2,10-bis((triethylsilyl)oxy)-9-methyl-10-(4-
bromophenyl)-decane-6-one 29 (0.100 g, 0.160 mmol) in THF (1.0 mL) at 0 °C.  
Tetrabutylammonium fluoride (1.0 M in THF) (1.3 mL, 1.278 mmol) was added and the 
reaction mixture was allowed to warm to rt while stirring.  The reaction was quenched with 
NaHCO3 and the layers were separated.  The aqueous layer was extracted 2x with Et2O.  The 
combined organic layers were dried over MgSO4, filtered and concentrated.  The product was 
purified by column chromatography (eluting with 50% Et2O:hex) to yield: 0.062 g, 0.1634 
mmol, 102.3 % and taken on immediate to the next reaction. 
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Spiroketal 23a: Preparation of (2R,3S,6R,8S,9R)-3-allyl-8-(4-bromophenyl)-2,9-
dimethyl-1,7-dioxaspiro[5.5]undecane 23a.  A vial was charged with (1S,2R,8S)-1-(4-
bromophenyl)-1-hydroxy-8-((R)-1-hydroxyethyl)-2-methylundec-10-en-5-one S8 (0.062 g, 
0.163 mmol) in wet dichloromethane (1.6 mL) at rt.  A catalytic amount of PPTS was added 
and the reaction mixture was stirred at rt.  When the reaction was complete by TLC, the 
solvent was removed in vacuo.  The crude reaction mixture was purified by column 
chromatography (eluting with 1.5% Et2O:hex) to yield: 0.056 g, 0.1476 mmol, 90.3 % as an 
inseparable 1:3 mixture of spiroketal diastereomers.  1H NMR ( 400 MHz, CD2Cl2): δ 7.46 
(d, J = 8.8 Hz, 2H), 7.25 (d, J = 8.8 Hz, 2H), 5.80-5.73 (m, 1H), 5.10-4.98 (m, 2H), 4.69 (d, J 
= 2.4 Hz, 1H), 4.54-4.50 (m, 1H), 2.30-2.22 (m, 1H), 2.21-2.10 (m, 2H), 2.03-1.97 (m, 2H), 
1.77-1.63 (m, 3H), 1.58-1.47 (m, 3H), 1.31 (dt, J = 4.0, 14.0, 14.0 Hz, 1H), 1.12 (d, J = 6.4 
Hz, 3H), 0.66 (d, J = 7.2 Hz, 3H); 13C (100 MHz, CD2Cl2): δ 142.0, 138.7, 131.3, 127.9, 
120.4, 115.7, 99.0, 75.6, 68.3, 36.9, 32.9, 31.5, 29.0, 27.9, 22.7, 22.2, 19.1, 11.9; MS (ESI): 
calculated for C20H27BrO2 [M+Na]+: 401.1, found 401.1. 
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Aldol Adduct 31: Preparation of (S)-1-((S)-4-benzyl-2-thioxothiazolidin-3-yl)-2-
((R)-1-hydroxy-2-methylpropyl)pent-4-en-1-one 31.  A 250 mL flame-dried round bottom 
flask under argon was charged with (S)-1-(4-benzyl-2-thioxothiazolidin-3-yl)pent-4-en-1-one 
27 (2.440 g, 8.373 mmol) in dichloromethane (70 mL) at 0 °C.  Titanium(IV) chloride (0.97 
mL, 8.791 mmol) was added and the reaction mixture was stirred at 0 °C for 5 min.  (–)-
Sparteine (1.9 mL, 8.373 mmol) was added and the reaction mixture was stirred at 0 °C for 
20 min.  The reaction mixture was cooled to -78 °C.  N-methylpyrrolidinone (0.80 mL, 8.373 
mmol) was added and the reaction mixture was stirred at - 78 °C for 10 min.  
Isobutyraldehyde 30 (0.84 mL, 9.210 mmol) was added and the reaction mixture was stirred 
at -78 °C for 1 h.  The reaction mixture was allowed to warm to 0 °C and stirred at 0 °C.  
When the reaction was complete by TLC, the reaction was quenched with 1/2 saturated 
NH4Cl.  The layers were separated and the aqueous layer was extracted 2x with CH2Cl2.  The 
combined organic layers were dried over Na2SO4, filtered and concentrated.  The product 
was purified by column chromatography (eluting with 7-18% EtOAc:hex) to yield: 2.100 g, 
5.7765 mmol, 69.0%.  1H NMR (400 MHz, CDCl3): δ 7.24-7.24 (m, 5H), 5.89-5.78 (m, 1H), 
5.18 (ddd, J = 4.4, 7.2, 10.8 Hz, 1H), 5.07-5.02 (m, 2H), 4.97 (d, J = 9.2 Hz, 1H), 3.69 (d, J = 
8 Hz, 1H), 3.29 (dd, J = 6.4, 11.2 Hz, 1H), 3.23 (dd, J = 4, 13.2 Hz, 1H), 3.03 (dd, J = 10.4, 
13.2 Hz, 1H), 2.92-2.86 (m, 2H), 2.54-2.40 (m, 2H), 1.81-1.72 (m, 1H), 1.04 (d, J = 6.4 Hz, 
3H), 0.91 (d, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 201.8, 178.2, 136.3, 135.4, 
129.4, 128.8, 127.2, 116.9, 75.8, 68.9, 45.1, 36.7, 32.5, 31.8, 31.2, 19.3, 19.0; IR (film): 3406 
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(br), 3059, 3027, 2960, 2924, 2870, 1682, 1261, 1164, 1042; MS (ESI): calculated for 
C19H25NO2S2 [M+Na]+: 386.1, found 386.1; [α]  = +189.62 (c 0.45, CH2Cl2). 
 
Protected Aldol Adduct S9: Preparation of (S)-1-((S)-4-benzyl-2-thioxothiazolidin-
3-yl)-2-((R)-2-methyl-1-((triethylsilyl)oxy)propyl)pent-4-en-1-one S9.  A 250 mL flame-
dried round bottom flask under argon was charged with (S)-1-((S)-4-benzyl-2-
thioxothiazolidin-3-yl)-2-((R)-1-hydroxy-2-methylpropyl)pent-4-en-1-one 31 (2.100 g, 5.777 
mmol) in dichloromethane (55 mL) at -78 °C.  2,6-Lutidine (1.34 mL, 11.553 mmol) was 
added followed by triethylsilyl trifluoromethanesulfonate (1.70 mL, 7.509 mmol) and the 
reaction mixture was allowed to warm to 0 °C while stirring.  The reaction was quenched 
with saturated aqueous NaHCO3.  The layers were separated and the aqueous layer was 
extracted 2x with CH2Cl2.  The combined aqueous layers were dried over Na2SO4, filtered 
and concentrated.  The product was purified by column chromatography (eluting with 1-5-
10% EtOAc:hex) to yield: 2.220 g, 4.6463 mmol, 80.4%.  1H NMR (400 MHz, CDCl3): δ 
7.33-7.23 (m, 5H), 5.91-5.80 (m, 1H), 5.231 (ddd, J = 4.0, 6.8, 10.4 Hz, 1H), 5.05-4.93 (m, 
3H), 4.12 (ddd, J = 2.8, 8 Hz, 1H), 3.23 (dd, J = 7.2, 11.2 Hz, 1H), 3.17 (dd, J = 3.6, 13.2 Hz, 
1H), 2.79 (d, J = 11.6 Hz, 1H), 2.65-2.61 (m, 1H), 2.24 (dt, J = 9.6, 13.2 Hz, 1H), 1.74 
(dddd, J = 3.2, 6.8, 13.6, 13.6 Hz, 1H, 1.00-0.95 (m, 12H), 0.89 (d, J = 6.8 Hz, 3H), 0.65 (q, 
J = 8.0 Hz, 6H);  13C NMR (100 MHz, CDCl3): δ 201.5, 176.0, 136.6, 135.8, 129.4, 128.8, 
127.1, 116.4, 77.2, 69.2, 46.6, 36.8, 36.7, 33.4, 31.9, 19.7, 17.4, 7.1, 5.5; IR (film): 3064, 
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3028, 2957, 2912, 2876, 1691, 1340, 1258, 741; MS (ESI): calculated for C25H39NO2S2Si 
[M+Na]+: 500.2, found 500.2; [α] 25D  = +154.17 (c 1.35, CH2Cl2). 
 
Aldehyde 32: Preparation of (S)-2-((R)-2-methyl-1-((triethylsilyl)oxy)propyl)pent-4-
enal 32.  A 100 mL flame-dried round bottom flask under argon was charged with (S)-1-((S)-
4-benzyl-2-thioxothiazolidin-3-yl)-2-((R)-2-methyl-1-((triethylsilyl)oxy)propyl)pent-4-en-1-
one S9 (2.220 g, 4.646 mmol) in dichloromethane (45 mL) at -78 °C.  Diisobutylaluminum 
hydride (1.0 M in hexane) (9.30 mL, 9.293 mmol) was added and the reaction mixture 
changed from bright yellow to colorless immediately.  The reaction was complete by TLC 
and quenched with Rochelle's salt and diluted with Et2O.  The biphasic mixture was stirred 
vigorously for at least 1 h.  The layers were separated and the aqueous layer was extracted 2x 
with Et2O.  The organic layer was dried over Na2SO4, filtered and concentrated.  The product 
was purified by column chromatography (7 - 30% EtOAc:hex) to yield: 1.002 g, 3.7045 
mmol, 79.7%.  1H NMR (500 MHz, CDCl3): δ 9.76 (d, J = 1.2 Hz, 1H), 5.77 (dddd, J = 5.2, 
5.2, 8.0, 13.6 Hz, 1H), 5.06-5.00 (m, 2H), 3.85 (t, J = 3.6 Hz, 1H), 2.54-2.45 (m, 2H), 2.27-
2.23 (m, 2H), 179-1.72 (m, 1H), 0.94 (t, J = 6.4 Hz, 9H), 0.88 (d, J = 5.2 Hz, 3H), 0.85 (d, J 
= 5.2 Hz, 3H), 0.59 (q, J = 6.4 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ .1, 136.1, 116.5, 
76.4, 55.8, 32.0, 29.1, 19.8, 17.8, 7.0, 5.2; IR (film): , 2959, 2913, 2878, 2723, 1728, 1470, 
1416, 1389, 1241, 1094, 1059, 1009, 741; MS (ESI): calculated for C15H30O2Si [M+Na]+: 
293.2, found 293.2; [α] 24D  = -30.22 (c 0.30, CH2Cl2). 
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Unsaturated Ketone S10: Preparation of (3R,4R,10R,11S,E)-4-allyl-3,11-
bis((triethylsilyl)oxy)-2,10-dimethyl-11-(4-bromophenyl)-5-undecene-7-one S10.  A 100 mL 
flame dried round bottom flask under argon was charged with dimethyl ((5R,6S)-6-(4-
bromophenyl)-5-methyl-2-oxo-6-((triethylsilyl)oxy)hexyl)phosphonate 11 (2.256 g, 4.446 
mmol) in THF (11 mL) at rt.  Barium hydroxide (0.533 g, 3.112 mmol) was added and the 
reaction mixture was stirred vigorously for 30 min.  (S)-2-((R)-2-methyl-1-
((triethylsilyl)oxy)propyl)pent-4-enal 32 (1.002 g, 3.705 mmol) was added as a 0.3 M 
solution in 40:1 THF:H2O (12.1 mL THF:0.3 mL H2O) and the reaction mixture was stirred 
vigorously at room temperature.  When the reaction was complete by TLC, the reaction 
mixture was filtered through Celite.  The filtrate was washed with NaHCO3 and the aqueous 
layer was back extracted 2x with EtOAc.  The aqueous layer was checked by TLC to ensure 
complete extraction of product.  The combined organic layers were dried over Na2SO4, 
filtered and concentrated.  The product was purified by column chromatography (eluting with 
8% EtOAc:hex) to yield: 1.914 g, 2.936 mmol, 79.3%.  1H NMR (400 MHz, CDCl3): δ 7.39 
(d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.0 Hz, 2H), 5.61 (dddd, J = 6.8, 6.8, 10.4, 17.6 Hz, 1H), 
4.98-4.93 (m, 2H), 4.45 (d, J = 4.8 Hz, 1H), 3.43 (dd, J = 4.0, 6.4 Hz, 1H), 2.55-2.40 (m, 
3H), 2.39-2.31 (m, 1H), 2.07-2.00 (m, 1H), 1.72-1.57 (m, 3H), 1.34-1.25 (m, 1H), 0.94 (t, J = 
8.0 Hz, 9H), 0.89-0.79 (m, 18H), 0.61 (q, J = 7.6 Hz, 6H), 0.47 (q, J = 7.8 Hz, 6H); 13C (125 
MHz, CDCl3): δ 200.2, 148.2, 143.2, 136.4, 130.9, 130.6, 128.3, 120.6, 116.3, 79.6, 78.1, 
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47.5, 41.1, 38.2, 34.5, 31.9, 27.5, 20.3, 16.7, 7.1, 6.8, 5.5, 4.8; IR (film): 2958, 2937, 2912, 
2877, 1699, 1681, 1632, 1487, 1463, 1415, 1240, 1071, 1010, 741; MS (ESI): calculated for 
C34H59BrO3Si2 [M+Na]+: 673.3, found 673.3; [α] 24D  = -21.74 (c 0.40, CH2Cl2). 
 
Saturated Ketone 33: Preparation of (3R,4S,10R,11S)-4-allyl-3,11-
bis((triethylsilyl)oxy)-2,10-dimethyl-11-(4-bromophenyl)-undecane-7-one 33.  A 200 mL 
flame-dried round bottom flask under argon was charged with copper(I) iodide (0.112 g, 
0.587 mmol) in 30 mL THF at -50 °C.  Methyllithium (0.37 mL, 0.587 mmol) was added 
followed sequentially by hexamethylphosphoramide (5.87 mL, 33.764 mmol) and 
diisobutylaluminum hydride (1.0 M in hexane) (7.63 mL, 7.634 mmol).  The reaction 
mixture was stirred at -50 °C for 30 min.  (3R,4R,10R,11S,E)-4-allyl-3,11-
bis((triethylsilyl)oxy)-2,10-dimethyl-11-(4-bromophenyl)-5-undecene-7-one S10 (1.914 g, 
2.936 mmol) was dissolved in 30 mL THF and added to the reaction mixture.  The reaction 
mixture was stirred at -50 °C for 1 h.  The reaction was monitored by 1H NMR for 
disappearance of the characteristic enone peaks.  The reaction was quenched with ice-cold 
1M HCl and the layers were separated immediately.  The organic layer was washed 2x with 
ice-cold 1M HCl and 3x with H2O.  The combined aqueous layers were back extracted 3x 
with Et2O.  The combined organic layers were dried over MgSO4, filtered and concentrated.  
The product was purified by column chromatography (eluting with 8% EtOAc:hex) to yield: 
1.828 g, 2.7954 mmol, 95.2%.  1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 8.0 Hz, 2H), 7.11 
(d, J = 8.0 Hz, 2H), 5.75 (dddd, J = 8.0, 8.0, 10.4, 18.0 Hz, 1H), 4.99-4.93 (m, 2H), 4.43 (d, J 
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= 4.4 Hz, 1H), 3.30 (dd, J = 3.2, 5.2 Hz, 1H), 2.42-2.17 (m, 5H), 1.93-1.85 (, 1H), 1.76-1.68 
(m, 1H), 1.65-1.52 (m, 5H), 1.50-1.42 (m, 1H), 1.29-1.22 (m, 1H), 0.94 (t, J = 8.0 Hz, 9H), 
0.87-0.78 (m, 18H), 0.58 (q, J = 8.0 Hz, 6H), 0.47 (q, J = 8.0 Hz, 6H);  13C NMR (100 MHz, 
CDCl3): δ 211.0, 143.1, 138.2, 130.8, 128.3, 120.6, 115.6, 79.4, 78.0, 41.2, 41.0, 40.9, 40.7, 
34.4, 31.5, 27.0, 25.1, 20.2, 18.8, 14.2, 7.1, 6.8, 5.5, 4.8; IR (film): 3076, 2956, 2912, 2876, 
2804,  1715, 1459, 1414, 1380, 1239, 1072, 1010, 740; MS (ESI): calculated for 
C34H61BrO3Si2 [M+Na]+: 675.3, found 675.3; [α] 25D  = -19.09 (c 0.8, CH2Cl2). 
 
Spiroketal 34a: Preparation of (2R,3S,6R,8S,9R)-3-allyl-8-(4-bromophenyl)-2-
isopropyl-9-methyl-1,7-dioxaspiro[5.5]undecane 34a.  A 1-dram vial was charged with 
(3R,4S,10R,11S)-4-allyl-2,10-dimethyl-3,11-bis((triethylsilyl)oxy)-11-(4-bromophenyl)-
undecan-7-one 33 (0.100 g, 0.153 mmol) in THF (2 mL) at 70 °C.  A catalytic amount of 
hydrofluoric acid (49% in H2O) was added and the reaction mixture was stirred at 70 °C until 
complete by TLC.  The reaction was quenched with saturated aqueous NaHCO3.  The layers 
were separated and the aqueous layer was extracted 2x with Et2O.  The combined organic 
layers were dried over MgSO4, filtered and concentrated. The product was purified by 
column chromatography (eluting with 1% EtOAc:hex) to yield: 0.030 g, 0.0736 mmol, 
48.2%.  1H NMR (500 MHz, CDCl3): δ 7.39 (d, J = 6.8 MHz, 2H), 7.16 (d, J = 6.8 Hz, 2H), 
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5.75-5.66 (m, 1H), 5.28 (d, J = 2.4 Hz, 1H), 5.05-4.97 (m, 2H), 3.06 (dd, J = 2.0, 8.0 Hz, 
1H), 2.27-2.17 (m, 2H), 2.12-2.04 (m, 2H), 1.94-1.90 (m, 1H), 1.82-1.66 (m, 5H), 1.50-1.37 
(m, 3H), 1.06 (d, J = 5.2 Hz, 3H), 0.82 (d, J = 5.2 Hz, 3H), 0.63 (d, J = 5.2 Hz, 3H); 13C 
NMR (125 MHz, CDCl3): δ 141.5, 137.7, 130.8, 127.5, 119.9, 115.8, 98.5, 81.0, 72.7, 33.1, 
32.4, 31.0, 29.5, 28.4, 25.5, 23.2, 21.8, 20.8, 18.3, 11.3; IR (film): 3069, 2955, 2867, 1488, 
1455, 1225, 1023, 902, 785; MS (ESI): calculated for C22H31BrO2 [M+Na]+: 429.1, found 
429.1. 
 
Dihydroxyketone S11: Preparation of (1S,2R,8S)-1-(4-bromophenyl)-1-hydroxy-8-
((R)-1-hydroxy-2-methylpropyl)-2-methylundec-10-en-5-one S11.  A 25 mL flame-dried vial 
under argon was charged with (3R,4S,10R,11S)-4-allyl-2,10-dimethyl-3,11-
bis((triethylsilyl)oxy)-11-(4-bromophenyl)-undecan-7-one 33 (0.100 g, 0.153 mmol) in THF 
(5 mL) at 0 °C.  Tetrabutylammonium fluoride (1.0 M in THF) (1.2 mL, 1.223 mmol) was 
added and the reaction mixture was allowed to warm to room temperature while stirring.  The 
reaction was quenched with saturated aqueous NaHCO3.  The layers were separated and the 
aqueous layer was extracted 2x with Et2O.  The combined organic layers were dried over 
MgSO4, filtered and concentrated.  The product was purified by column chromatography 
(eluting with 30% EtOAc:hex) to yield: 0.030 g, 0.0705 mmol, 46.1 %, along with an equal 
amount of mono-protected diol.  The bis-deprotected diol was taken on immediately to the 
next reaction. 
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Spiroketal 34: Preparation of (2R,3S,6R,8S,9R)-3-allyl-8-(4-bromophenyl)-2-
isopropyl-9-methyl-1,7-dioxaspiro[5.5]undecane 34.  a 1-dram vial was charged with 
(1S,2R,8S)-1-(4-bromophenyl)-1-hydroxy-8-((R)-1-hydroxy-2-methylpropyl)-2-
methylundec-10-en-5-one S11 (0.030 g, 0.071 mmol) in wet dichloromethane (3.5 mL) at rt.  
A catalytic amount of PPTS was added and the reaction mixture was stirred at rt.  The 
solvent was removed and the product was purified by column chromatography (eluting with 
2.5% EtOAc:hex) to yield: 0.021 g, 0.052 mmol, 34%.  1H NMR (500 MHz, CDCl3): δ 7.44 
(d, J = 6.8, 2H), 7.17 (d, J = 6.8 Hz, 2H), 5.78-5.69 (m, 1H), 5.05-4.97 (m, 2H), 4.63 (d, J = 
2.0 Hz, 1H), 3.96-2.16 (m, 1H), 2.22-2.07 (m, 3H), 2.01-1.89 (m, 2H), 1.81-1.73 (m, 1H), 
1.70-1.63 (m, 3H), 1.59-1.48 (m, 3H), 1.34-1.27 (m, 1H), 1.05 (d, J = 5.2 Hz, 3H), 0.83 (d, J 
= 5.6 Hz, 3H), 0.64 (d, J = 5.2 Hz, 3H); 13C NMR (125 MHz, CDCl3): δ141.5, 138.0, 131.1, 
127.2, 120.1, 115.6, 98.2, 77.8, 75.1, 32.7, 32.6, 30.8, 29.1, 282., 27.6, 22.5, 21.5, 20.4, 18.1, 
11.4; IR (film): 3072, 2955, 287, 1730, 1489, 1455, 1380, 1226, 1125, 1009, 903, 787, 787; 
MS (ESI): calculated for C22H31BrO2 [M+Na]+: 429.1, found 429.1; [α] 25D  = -77.21 (c 0.29, 
CH2Cl2). 
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Aldol Adduct 53: Preparation of (R)-3-hydroxy-1-((R)-4-mesityl-2-
thioxothiazolidin-3-yl)hex-5-en-1-one 53.  A 250 mL flame-dried round bottom flask under 
argon was charged with (R)-1-(4-mesityl-2-thioxothiazolidin-3-yl)ethanone 51 (5.127 g, 
18.349 mmol) in dichloromethane (90 mL) at -78 °C.  Titanium(IV) chloride (2.0 mL, 18.349 
mmol) was added followed by diisopropyl ethyl amine (3.2 mL, 18.349 mmol) and the 
reaction mixture was stirred for 30 min at -78 °C. 3-Butenal 20 (in CH2Cl2) (1.169 g, 16.681 
mmol) was cannulated in to the reaction mixture and the reaction mixture was stirred for 1h 
at -78 °C.  The reaction was quenched with 1/2 saturated aqueous NH4Cl.  The layers were 
separated and the aqueous layer was extracted 2x with CH2Cl2.  The combined organic layers 
were dried over Na2SO4, filtered and concentrated.  The product was purified by column 
chromatography (eluting with 10-15% EtOAc:hex) to yield: 4.665 g, 13.348 mmol, 80%.  1H 
NMR (400 MHz, CDCl3): δ 6.83 (s, 2H), 6.36 (t, J = 10.0 Hz, 1H), 5.75 (dddd, J = 6.8, 6.8, 
9.2, 16.4 Hz, 1H), 5.10-5.08 (m, 1H), 5.06-5.04 (m, 1H), 3.97-3.90 (m, 1H), 3.56 (dd, J = 
10.4, 11.6 Hz, 1H), 3.53 (dd, J = 9.2, 17.6 Hz, 1H), 3.31 (dd, J = 9.2, 11.2 Hz, 1H), 3.17 (dd, 
J = 2.8, 17.2 Hz, 1H), 2.81 (d, J = 4.0 Hz, 1H), 2.37 (s (br), 6H), 2.26-2.14 (m, 2H), 2.23 (s, 
3H); 13C NMR (100 MHz, CDCl3): δ 201.6, 174.5, 137.7, 133.8, 132.5, 128.2, 117.9, 67.9, 
67.6, 45.8, 40.7, 32.4, 20.7, 20.1; IR (film): 3447 (br), 3074, 3006, 2971, 2921, 2868, 2734, 
1705, 1610, 1371, 1260, 1177, 1049, 912, 731; MS (ESI): calculated for C18H23NO2S2 
[M+Na]+: 372.1, found 372.1; [α] 24D  = -112.10 (c 0.95, CH2Cl2). 
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Protected Aldol Adduct 56: Preparation of (R)-3-((tert-butyldimethylsilyl)oxy)-1-
((R)-4-mesityl-2-thioxothiazolidin-3-yl)hex-5-en-1-one 56.  A 500 mL flame-dried round 
bottom flask under argon was charged with (R)-3-hydroxy-1-((R)-4-mesityl-2-
thioxothiazolidin-3-yl)hex-5-en-1-one 53 (4.600 g, 13.161 mmol) in dichloromethane (130 
mL) at -78 °C.  2,6-Lutidine (4.0 mL, 26.323 mmol) was added followed by tert-
butyldimethylsilyl trifluoromethanesulfonate (3.4 mL, 17.110 mmol) and the reaction 
mixture was allowed to warm to 0 °C while stirring.  The reaction was quenched with 
saturated aqueous NaHCO3.  The layers were separated and the aqueous layer was extracted 
2x with CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered and 
concentrated.  The product was purified by column chromatography (eluting with 1-5-10% 
EtOAc:hex) to yield: 5.400 g, 11.6437 mmol, 88.5%.  1H NMR (400 MHz, CDCl3): δ 6.82 (s, 
2H), 3.39 (t, J = 9.6 Hz, 1H), 5.67 (dddd, J = 6.8, 6.8, 10.4, 17.2 Hz, 1H), 4.94-4.76 (m, 2H), 
4.18-4.12 (m, 1H), 3.67 (dd, J = 4.8, 17.6 Hz, 1H), 3.54 (dd, J = 10.4, 11.2 Hz, 1H), 3.31 (dd, 
J = 9.2, 11.2 Hz, 1H), 3.00 (dd, J = 7.6, 17.6 Hz, 1H), 2.38 (s (br), 6H), 2.22 (s, 3H), 1.93-
1.90 (m, 2H), 0.82 (s, 9H), -0.01 (s, 3H), -0.02 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 
201.0, 173.2, 137.8, 134.4, 132.6, 117.2, 68.5, 67.9, 47.0, 41.1, 32.4, 25.8, 20.7, 20.3, 18.0, -
4.7; IR (film): 3075, 2954, 2928, 2856, 1710, 1371, 1257, 1177, 836, 776; MS (ESI): 
calculated for C24H37NO2S2Si [M+Na]+: 486.2, found 486.2; [α] 24D  = -99.98 (c 0.60, CH2Cl2). 
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Aldehyde 57: Preparation of (R)-3-((tert-butyldimethylsilyl)oxy)hex-5-enal 57.  A 
500 mL flame-dried round bottom flask under argon was charged with (R)-3-((tert-
butyldimethylsilyl)oxy)-1-((R)-4-mesityl-2-thioxothiazolidin-3-yl)hex-5-en-1-one 56 (5.400 
g, 11.644 mmol) in dichloromethane (120 mL) at -78 °C.  Diisobutylaluminum hydride (1.0 
M in hexane) (23.3 mL, 23.287 mmol) was added and the yellow color of the reaction 
mixture immediately changed to colorless.  The reaction was quenched with saturated 
aqueous Rochelle's salt and diluted with Et2O.  The biphasic mixture was stirred vigorously 
for at least 1 h. The layers were separated and the aqueous layer was extracted 2x with Et2O.  
The combined organic layers were dried over Na2SO4, filtered and concentrated.  The 
product was purified by column chromatography (eluting with 4-25% acetone:hex) to yield: 
1.976 g, 8.6515 mmol, 74.3%.  1H NMR (300 MHz, CDCl3): δ 9.78 (t, J = 3.2 Hz, 1H), 5.76 
(dddd, J = 9.6, 9.6, 14.4, 22.0 Hz, 1H), 5.09-5.03 (m, 2H), 4.24 (pentet, J = 8.0 Hz, 1H), 2.52 
(dd, J = 1.2, 3.6 Hz, 1H), 2.50 (d, J = 3.4 Hz, 1H), 2.28 (ddt, J = 1.6, 1.6, 8.0, 9.6 Hz, 2H), 
0.85 (s, 9H), 0.06 (s, 3H), 0.04 (s, 3H); 13C NMR (100 MHz, CDCl3): δ 202.0, 133.8, 118.1, 
67.7, 50.3, 42.3, 25.7, 17.9, -4.4, -4.8; IR (film): 3079, 2956, 2930, 2897, 2858, 2723, 1729, 
1472, 1362, 1256, 1102, 838, 777; MS (ESI): calculated for C12H24O2Si [M+Na]+: 251.1, 
found 251.2; [α] 23D  = -19.27 (c 0.60, CH2Cl2). 
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Iterative Aldol Adduct 58: (3S,5R)-5-((tert-butyldimethylsilyl)oxy)-3-hydroxy-1-
((S)-4-mesityl-2-thioxothiazolidin-3-yl)oct-7-en-1-one 58.  A 100 mL flame-dried round 
bottom flask under argon was charged with (S)-1-(4-mesityl-2-thioxothiazolidin-3-
yl)ethanone 50 (1.976 g, 7.072 mmol) in dichloromethane (35 mL) at -78 °C.  Titanium(IV) 
chloride (0.78 mL, 7.072 mmol) was added followed by diisopropyl ethyl amine (1.23 mL, 
7.072 mmol) and the reaction mixture was stirred at -78 °C for 30 min.  (R)-3-((tert-
butyldimethylsilyl)oxy)hex-5-enal 57 (1.065 g, 4.661 mmol) was added and the reaction 
mixture was stirred for 1 h at -78 °C.  The reaction was quenched with 1/2 saturated NH4Cl.  
The layers were separated and the aqueous layer was extracted 2x with CH2Cl2.  The 
combined organic layers were dried over Na2SO4, filtered and concentrated.  The product 
was purified by column chromatography (eluting with 7% EtOAc:hex) to yield: 2.083 g, 
4.1018 mmol, 88.0%.  1H NMR (400 MHz, CDCl3): δ 6.81 (s, 2H), 6.34 (t, J = 10.0 Hz, 1H), 
5.64 (dddd, J = 3.6, 3.6, 10.8, 13.6 Hz, 1H), 5.01-4.96 (m, 2H), 4.16-4.09 (m, 1H), 3.94-3.89 
(m, 1H), 3.55 (dd, J = 10.4, 11.2 Hz, 1H), 3.47 (dd, J = 8.4, 17.2 Hz, 1H), 3.34-3.29 (m, 2H), 
3.11 (dd, J = 3.6, 17.2 Hz, 1H), 2.37 (s (br), 6H), 2.22-2.19 (m, 5H), 1.57-1.50 (m, 1H), 1.34 
(ddd, J = 2.0, 7.6, 14.0 Hz), 0.83 (s, 9H), 0.02 (s, 3H), -0.02 (s, 3H); 13C NMR (100 MHz, 
CDCl3): δ 201.3, 174.4, 137.7, 134.4, 132.5, 130.8, 128.3, 117.2, 69.5, 68.0, 65.1, 47.3, 42.2, 
41.8, 32.6, 25.8, 20.7, 20.2, 17.9, -4.5, -4.9; IR (film): 3490, 3075, 2953, 2928, 2856, 1705, 
1462, 1258, 1129, 911, 837, 776, 732; MS (ESI): calculated for C26H41NO3S2Si [M+Na]+: 
530.2, found 530.2; [α] 24D  = +63.22 (c 0.55, CH2Cl2). 
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Protected Aldol Adduct 59: Preparation of (3S,5R)-5-((tert-butyldimethylsilyl)oxy)-
1-((S)-4-mesityl-2-thioxothiazolidin-3-yl)-3-((trimethylsilyl)oxy)oct-7-en-1-one 59.  A 50 
mL flame-dried round bottom flask under argon was charged with (3S,5R)-5-((tert-
butyldimethylsilyl)oxy)-3-hydroxy-1-((S)-4-mesityl-2-thioxothiazolidin-3-yl)oct-7-en-1-one 
58 (2.083 g, 4.102 mmol) in dichloromethane (8 mL) at 0 °C.  Triethylamine (1.14 mL, 8.204 
mmol) was added followed by chlorotrimethylsilane (0.91 mL, 7.178 mmol) and a catalytic 
amount of dimethylamino pyridine.  The reaction mixture was stirred for 1 h at 0 °C.  The 
reaction was quenched with saturated aqueous NaHCO3.  The layers were separated and the 
aqueous layer was extracted 2x with CH2Cl2.  The combined organic layers were dried over 
Na2SO4, filtered and concentrated.  The product was purified by column chromatography 
(eluting with 7% EtOAc:hex) to yield: 2.148 g, 3.7034 mmol, 90.3%.  1H NMR (400 MHz, 
CDCl3): δ 6.80 (s, 2H), 6.34 (t, J = 9.6 Hz, 1H), 5.67 (dddd, J = 7.2, 7.2, 10.4, 17.6 Hz, 1H), 
5.01-4.95 (m, 2H), 4.22-4.16 (m, 1H), 3.69-3.65 (m, 1H), 3.60 (dd, J = 5.2, 17.2 Hz, 1H), 
3.54 (dd, J = 10.8, 11.2 Hz, 1H), 3.31 (dd, J = 9.6, 11.2 Hz, 1H), 3.06 (dd, J = 7.6, 17.6 Hz, 
1H), 2.37 (s (br), 6H), 2.22 (s, 3H), 2.13-2.01 (m, 2H), 1.36 (ddd, J = 4.4, 8.4, 14.0 Hz, 1H), 
1.03 (ddd, J = 3.6, 7.2, 13.6 Hz, 1H), 0.80 (s, 9H), 0.05 (s, 9H), -0.05 (s, 3H), -0.07 (s, 3H); 
13C NMR (100 MHz, CDCl3): δ 200.8, 172.7, 137.7, 135.0, 132.6, 128.3, 116.7, 69.2, 67.8, 
66.9, 48.4, 44.6, 42.6, 32.6, 25.8, 20.8, 20.2, 18.0, 0.6, -3.9, -4.4; IR (film): 3075, 2955, 
2928, 2856, 1715, 1462, 1371, 1253, 839, 774; MS (ESI): calculated for C29H49NO3S2Si2 
[M+Na]+: 602.3, found 602.3; [α] 24D  = +47.53 (c 0.50, CH2Cl2). 
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β-Ketophosphonate 60: Preparation of dimethyl ((4S,6R)-6-((tert-
butyldimethylsilyl)oxy)-2-oxo-4-((trimethylsilyl)oxy)non-8-en-1-yl)phosphonate 60.  A 200 
mL flame-dried round bottom flask fitted with a jacketed addition funnel was charged with 
dimethyl methylphosphonate 19 (2.0 mL, 18.517 mmol) in THF (40 mL) at -78 °C.  n-
Butyllithium (1.6 M, 11.5 mL, 18.332 mmol) was cooled to -78 °C in the jacketed addition 
funnel and added dropwise to the reaction mixture to ensure the internal temperature 
remained constant.  The reaction mixture was stirred at -78 °C for 1 h.  (3S,5R)-5-((tert-
butyldimethylsilyl)oxy)-1-((S)-4-mesityl-2-thioxothiazolidin-3-yl)-3-((trimethylsilyl)oxy)oct-
7-en-1-one 59 (2.148 g, 3.703 mmol) was cooled to -78 °C in the jacketed addition funnel 
and added dropwise to the reaction mixture to ensure the internal temperature remained 
constant.  The reaction mixture was stirred at -78 °C.  When the reaction was complete by 
TLC, the reaction was quenched with saturated aqueous NH4Cl.  The layers were separated 
and the aqueous layer was extracted 2x with Et2O.  The combined organic layers were dried 
over MgSO4, filtered and concentrated.  The product was purified by column 
chromatography (eluting with 30-75% EtOAc:hex) to yield: 1.593 g, 3.4133 mmol, 92.2%.  
Due to the sensitivity of the product, the phosphonate was taken on immediately to the next 
step.  1H NMR (400 MHz, CDCl3): δ 5.83-5.72 (m, 1H), 5.05-5.00 (m, 2H), 4.25-4.17 (m, 
1H), 3.77-3.74 (m, 7H), 3.16-3.02 (m, 2H), 2.80-2.67 (m, 2H), 2.28-2.14 (m, 2H), 1.67-1.51 
(m, 2H), 0.86 (s, 9H), 0.08 (s, 9H), 0.05 (s, 6H). 
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Aldol Adduct 65: Preparation of (R)-3-hydroxy-1-((R)-4-mesityl-2-
thioxothiazolidin-3-yl)pentan-1-one 65.  A 500 mL flame dried round bottom flask under 
argon was charged with (R)-1-(4-mesityl-2-thioxothiazolidin-3-yl)ethanone 51 (9.137 g, 
32.700 mmol) in dichloromethane (160 mL) at -78 °C.  Titanium(IV) chloride (3.6 mL, 
32.700 mmol) was added followed by diisopropyl ethyl amine (5.7 mL, 32.700 mmol) and 
the reaction mixture was stirred at -78 °C for 30 min.  Propionaldehyde 64 (2.2 mL, 29.727 
mmol) was added and the reaction mixture was stirred at -78 °C for 1 h.  The reaction was 
quenched with 1/2 saturated NH4Cl.  The layers were separated and the aqueous layer was 
extracted 2x with CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered 
and concentrated.  The product was purified by column chromatography (eluting with 10-
20% EtOAc:hex) to yield: 8.948 g, 26.5126 mmol, 89.2%.  1H NMR (400 MHz, CDCl3): δ 
6.84 (s, 2H), 6.36 (t, J = 9.6 Hz, 1H), 3.78-3.76 (m, 1H), 3.56 (dd, J = 10.4, 11.2 Hz, 1H), 
3.50 (dd, J = 9.2, 17.2 Hz, 1H), 3.31 (dd, J = 9.6, 11.6 Hz, 1H), 3.15 (dd, J = 2.8, 17.6 Hz, 
1H), 2.84 (s, 1H), 2.381 (s (br), 6H), 2.24 (s, 3H), 1.54-1.37 (m, 2H), 0.88 (t, J = 7.2 Hz, 3H). 
 
Isobutyl Ester 66: Preparation of (R)-isobutyl 3-hydroxypentanoate 66.  A 250 mL 
flame-dried round bottom flask under argon was charged with (R)-3-hydroxy-1-((R)-4-
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mesityl-2-thioxothiazolidin-3-yl)pentan-1-one 65 (8.948 g, 26.513 mmol) in dichloromethane 
(50 mL) at rt.  Imidazole (2.707 g, 39.769 mmol) was added followed by isobutanol (24.5 
mL, 265.126 mmol) and a catalytic amount of dimethylamino pyridine.  The reaction mixture 
was stirred at room temperature overnight.  The reaction was quenched with H2O.  The layers 
were separated and the aqueous layer was extracted 2x with CH2Cl2.  The combined aqueous 
layers were dried over Na2SO4, filtered and concentrated.  The product was purified by 
column chromatography (eluting with 1-3-5% Et2O:CH2Cl2) to yield: 3.880 g, 22.265 mmol, 
84%.  1H (400 MHz, CDCl3): δ 3.89-3.84 (m, 3H), 3.35 (d, J = 8.0 Hz, 1H), 3.04 (s, 1H), 
2.48 (dd, J = 2.4, 15.6 Hz, 1H), 2.37 (dd, J = 9.2, 16.4 Hz, 1H), 1.94-1.84 (m, (1H), 1.76-
1.68 (m, 1H), 1.56-1.39 (m, 2H), 0.94-0.86 (m, 6H). 
 
Alkylation Product 67: Preparation of (2R,3R)-isobutyl 3-hydroxy-2-
methylpentanoate 67.  A 50 mL flame-dried round bottom flask under argon was charged 
with diisopropyl amine (3.23 mL, 22.957 mmol) in THF (11 mL) at 0 °C.  n-Butyllithium 
(1.6 M, 14.35 mL, 22.957 mmol) was added and the reaction mixture was stirred at 0 °C for 
10 min, rt for 10 min, and 0 °C for 10 min.  (R)-Isobutyl 3-hydroxypentanoate 66 (1.000 g, 
5.739 mmol) was added and the reaction mixture was stirred at -40 °C for 20 min.  
Iodomethane (3.53 mL, 57.392 mmol) was added and the reaction mixture was stirred at -78 
°C for 1 h.  The reaction mixture was warmed to -40 °C and stirred for 3 days.  The reaction 
was quenched with saturated aqueous NH4Cl.  The layers were separated and the aqueous 
layer was extracted 2x with EtOAc.  The combined organic layers were washed with brine, 
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dried over Na2SO4, filtered and extracted.  The product was purified by column 
chromatography (eluting with 10-15% EtOAc:hex) to yield: 0.595 g, 3.1605 mmol, 55.1 % as 
an 8.4:1 mixture of diastereomers.  1H NMR (400 MHz, CDCl3): δ 3.87 (d, J = 6.8 Hz, 2H), 
3.57 (dddd, J = 4.0, 6.8, 6.8, 8.4 Hz, 1H), 2.61 (d, J = 6.8 Hz, 1H), 2.53 (pentet, J = 7.2 Hz, 
1H), 1.92 (septet, J = 6.8 Hz, 1H), 1.60-1.50 (m, 1H), 1.48-1.39 (m, 1H), 1.2 (d, J = 7.2 Hz, 
3H), 0.96 (t, J = 7.6 Hz, 3H), 0.92 (d, J = 6.8 Hz, 6H). 
 
Protected Isobutyl Ester 68: Preparation of (2R,3R)-isobutyl 2-methyl-3-
((triethylsilyl)oxy)pentanoate 68.  A 100 mL flame-dried round bottom flask under argon 
was charged with (2R,3R)-isobutyl 3-hydroxy-2-methylpentanoate 67 (0.545 g, 2.895 mmol) 
in dichloromethane (30 mL) at -78 °C.  2,6-Lutidine (0.74 mL, 6.369 mmol) was added 
followed by triethylsilyl trifluoromethanesulfonate (0.98 mL, 4.342 mmol) and the reaction 
mixture was allowed to warm to 0 °C while stirring.  The reaction was quenched with 
saturated aqueous NaHCO3.  The layers were separated and the aqueous layer was extracted 
2x with CH2Cl2.  The combined organic layers were dried over Na2SO4, filtered and 
concentrated at 0 °C.  The product was purified by column chromatography (eluting with 1-
3% Et2O:pentanes) to yield: 0.840 g, 2.778 mmol, 96%.  1H NMR (400 MHz, CDCl3): δ 3.93 
(dt, J = 4.4, 6.4, 6.4 Hz, 1H), 3.82 (d, J = 6.8 Hz, 2H), 2.62 (pentet, J = 7.2 Hz, 1H), 1.91 
(septet, J = 6.8 Hz, 1H), 1.52-1.37 (m, 2H), 1.07 (d, J = 7.2 Hz, 3H), 0.93 (t, J = 8.0 Hz, 9H), 
0.91 (d, J = 6.4 Hz, 6H), 0.87 (t, J = 7.2 Hz, 3H), 0.57 (q, J = 8.0 Hz, 6H). 
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Aldehyde 45 Preparation of (2R,3R)-2-methyl-3-((triethylsilyl)oxy)pentanal 45.  A 
50 mL flame-dried flask under argon was charged with (2R,3R)-isobutyl 2-methyl-3-
((triethylsilyl)oxy)pentanoate 68 (0.730 g, 2.413 mmol) in dichloromethane (16 mL) at -78 
°C.  Diisobutylaluminum hydride (1M in hexane) (4.83 mL, 4.826 mmol) was added quickly 
and the reaction was monitored by TLC.  The reaction was quenched with saturated aqueous 
Rochelle's salt.  The biphasic mixture was stirred vigorously for at least 1.5 h.  The layers 
were separated and the aqueous layer was extracted 2x with CH2Cl2.  The combined organic 
layers were dried over Na2SO4, filtered and concentrated at 0 °C.  The product was purified 
by column chromatography (eluting with 3-30% Et2O:pentanes) to yield: 0.377 g, 1.6361 
mmol, 67.8%.  An additional 0.169 g, 0.727 mmol (30.1%) of the over-reduced alcohol 69 
was isolated.  Aldehyde 45: 1H NMR (300 MHz, CDCl3): δ 9.74 (d, J = 3.2 Hz, 1H), 3.87 (q, 
J = 7.6 Hz, 1H), 2.54-2.44 (m, 1H), 1.59-1.48 (m, 2H), 1.05 (d, J = 9.6 Hz, 3H), 9.32 (t, J = 
10.8 Hz, 9H), 0.89 (t, J = 10.0, 3H), 0.58 (q, J = 10.8 Hz, 6H).  Alcohol 69: 1H NMR (300 
MHz, CDCl3): δ 3.74 (dd, J = 4.4, 14.4 Hz, 1H), 3.63 (q, J = 7.6 Hz, 1H), 3.51 (dd, J = 7.2, 
14.4 Hz, 1H), 2.94 (s, 1H), 1.80-1.68 (m, 1H), 1.57 (dq, J = 7.6, 10.0, 10.0, 10.0 Hz, 1H), 
0.97-0.92 (m, 12H), 0.83 (t, J = 10.0, 3H), 0.60 (q, J = 10.4 Hz, 6H). 
 
 
 123 
 
 
Aldehyde 45: Preparation of (2R,3R)-2-methyl-3-((triethylsilyl)oxy)pentanal 45.  A 
20 mL flame-dried vial under argon was charged with (2S,3R)-2-methyl-3-
((triethylsilyl)oxy)pentan-1-ol 69 (0.105 g, 0.452 mmol) in wet dichloromethane (4.5 mL) at 
rt.  Sodium bicarbonate (0.379 g, 4.517 mmol) was added followed by Dess-Martin 
Periodinane (0.383 g, 0.903 mmol) and the reaction mixture was stirred at rt for 30 min.  The 
reaction was quenched with 5:1 Na2S2O3:NaHCO3 in H2O.  The layers were separated and 
the aqueous layer was extracted 2x with CH2Cl2.  The combined organic layers were dried 
over Na2SO4, filtered and concentrated at 0 °C.  The product was purified by column 
chromatography (eluting with 5% Et2O:pentanes) to yield: 0.065 g, 0.2821 mmol, 62.4%.  
NMR Data matches that reported above. 
 
Diol S12: Preparation of (2S,3R)-2-methylpentane-1,3-diol S12.  A 1-dram flame-
dried vial under argon was charged with (2S,3R)-2-methyl-3-((triethylsilyl)oxy)pentan-1-ol 
69 (0.050 g, 0.215 mmol) in THF (2.2 mL) at rt.  Tetrabutylammonium fluoride (1.0 M in 
THF) (2.2 mL, 2.151 mmol) was added and the reaction mixture was stirred at rt.  When the 
reaction was complete by TLC, the solvent was removed under reduced pressure at 0 °C and 
the crude reaction mixture was loaded directly onto a silica gel column for purification.  The 
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product was purified by column chromatography (eluting with 75-100% Et2O:pentanes) to 
yield: 0.023 g, 0.1946 mmol, 90.5%.  The product was taken immediately on to the next 
reaction. 
 
Dioxane 71: Preparation of (4R,5S)-4-ethyl-2-(4-methoxyphenyl)-5-methyl-1,3-
dioxane 71.  A 1 dram flame-dried vial under argon was charged with (2S,3R)-2-
methylpentane-1,3-diol S12 (0.023 g, 0.195 mmol) in benzene (0.65 mL) at rt.  p-
Methoxybenzaldehyde dimethyl acetal 70 (0.17 mL, 0.973 mmol) was added followed by a 
catalytic amount of PPTS.  The reaction mixture was stirred at rt until complete by TLC.  
The crude reaction mixture was loaded directly on a silica gel column for communication.  
The product was purified by column chromatography (eluting with 5% Et2O:pentanes) to 
yield: 0.025 g, 0.1058 mmol, 54.4%.  1H NMR (400 MHz, CDCl3): δ 7.41 (d, J = 8.8 Hz, 
2H), 6.87 (d, J = 8.8 Hz, 2H), 5.43 (s, 1H); 4.07 (dd, J = 4.8, 11.2 Hz, 1H), 3.78 (s, 3H), 3.46 
(t, J = 11.2 Hz, 1H), 3.32 (dt, J = 2.8, 10.8, 10.8 Hz, 1H), 1.90-1.81 (m, 1H), 1.80-1.72 (m, 
1H), 1.58-1.47 (m, 1H), 1.00 (t, J = 7.6 Hz, 3H), 0.76 (d, J = 6.8 Hz, 3H). 
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Protected Aldehyde 72: Preparation of (2R,3R)-3-((tert-butyldimethylsilyl)oxy)-2-
methylpentanal 72.  A 20 mL flame-dried vial under argon was charged with 
propionaldehyde 64 (0.73 mL, 10.003 mmol) in dimethyl formamide (5 mL) at 0 °C.  D-
proline (0.058 g, 0.500 mmol) was added and the reaction mixture was stirred overnight at 4 
°C.  2,6-Lutidine (2.9 mL, 25.009 mmol) was added followed by tert-
butylchlorodimethylsilane (2.262 g, 15.005 mmol) and the reaction mixture was stirred 
overnight at 4 °C.  The reaction was quenched with saturated aqueous NaHCO3.  The layers 
were separated and the aqueous layer was extracted 2x with Et2O.  The combined organic 
layers were dried over Na2SO4, filtered and concentrated at 0 °C.  The product was purified 
by column chromatography (eluting with 3% Et2O:pentanes) to yield: 0.368 g, 1.5971 mmol, 
31.9 % as an inseparable 5:1 mixture of diastereomers.  1H NMR (500 MHz, CDCl3): δ 9.73 
(d, J = 1.6 Hz, 1H), 3.84 (q, J = 4.4 Hz, 1H), 2.52-2.47 (m, 1H), 1.59-1.46 (m, 2H), 1.05 (d, J 
= 5.6 Hz, 3H), 0.90-0.84 (m, 12H), 0.04 (d, J = 5.6 Hz, 6H); 13C NMR (125 MHz, CDCl3): δ 
205.3, 74.5, 50.5, 27.4, 25.8, 18.0, 10.5, 8.9, -4.3, -4.8; IR (film): 2959, 2932, 2884, 2859, 
2710, 1730, 1464, 1256, 838, 775; MS (ESI): calculated for C12H26O2Si [M+Na]+: 253.2, 
found 253.1. 
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Unsaturated Ketone S13: Preparation of (4R,6S,11S,12R)-11-methyl-6-
(trimethylsilyl)oxy-4,12-bis((tert-butyldimethylsilyl)oxy)-tetradec-1,9-dien-8-one S13.  A 50 
mL flame-dried round bottom flask under argon was charged with dimethyl ((4S,6R)-6-((tert-
butyldimethylsilyl)oxy)-2-oxo-4-((trimethylsilyl)oxy)non-8-en-1-yl)phosphonate 60 (1.987 
g, 4.258 mmol) in THF (10 mL) at rt.  Barium hydroxide (0.533 g, 3.111 mmol) was added 
and the reaction mixture was stirred at rt for 30 min.  (2R,3R)-3-((tert-
butyldimethylsilyl)oxy)-2-methylpentanal 72 (0.755 g, 3.275 mmol) was added as a 0.3 M 
solution in 40:1 THF:H2O (10.5 mL THF:0.3 mL H2O).  The reaction mixture was stirred 
vigorously until complete by TLC.  The reaction mixture was diluted with Et2O and filtered 
through Celite.  The filtrate was washed with saturated aqueous NaHCO3.  The combined 
aqueous layers were back extracted 2x with EtOAc, and the aqueous layer was checked by 
TLC to ensure complete extraction of product.  The combined organic layers were dried over 
Na2SO4, filtered and concentrated.  The product was purified by column chromatography 
(eluting with 2-5% EtOAc:hex) to yield: 1.645 g, 2.880 mmol, 88%.  1H NMR (400 MHz, 
CDCl3): δ 6.78 (dd, J = 8.0, 16.0 Hz, 1H), 6.05 (d, J = 16.4 Hz, 1H), 5.83-5.73 (m, 1H), 5.05-
5.01 (m, 2H), 4.27-4.23 (m, 1H), 3.79-3.73 (m, 1H), 3.53-3.49 (m, 1H), 2.78 (dd, J = 7.2, 
14.8 Hz, 1H), 2.55 (dd, J = 4.8, 15.2 Hz, 1H), 2.47-2.42 (m, 1H), 2.27-2.17 (m, 2H), 1.69-
1.54 (m, 2H), 1.49-1.40 (m, 1H), 1.38-1.30 (m, 1H), 1.03 (d, J = 6.8 Hz, 3H), 0.87-0.80 (m, 
21H), 0.06 (s, 9H), 0.04 (s, 6H), 0.02 (s, 6H); 13C NMR (100 MHz, CDCl3): δ 198.7, 149.9, 
134.8, 131.1, 117.1, 76.6, 69.6, 67.2, 48.1, 45.5, 42.3, 41.6, 27.1, 18.1, 18.1, 15.6, 9.7, 0.5,    
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-4.1, -4.3, -4.4, -4.6; IR (film): 2957, 2930, 2858, 1669, 1625, 1472, 1379, 1254, 1108, 838, 
775; MS (ESI): calculated for C30H62O4Si3 [M+Na]+: 593.4, found 593.4; [α] 25D  = -10.59 (c 
0.11, CH2Cl2). 
 
Saturated Ketone 73: Preparation of (4R,6S,11S,12R)-4,12-bis((tert-
butyldimethylsilyl)oxy)-6-((trimethylsilyl)oxy)-11-methyl-tetradec-1-ene-8-one 73.  A 200 
mL flame-dried round bottom flask under argon was charged with copper(I) iodide (0.083 g, 
0.435 mmol) in 25 mL THF at -50 °C.  Methyllithium (0.27 mL, 0.435 mmol) was added 
followed sequentially by hexamethylphosphoramide (4.4 mL, 24.991 mmol) and 
diisobutylaluminum hydride (1.0 M in hexane) (5.7 mL, 5.650 mmol).  The reaction mixture 
was stirred at -50 °C for 30 min.  (4R,6S,11S,12R)-11-methyl-6-(trimethylsilyl)oxy-4,12-
bis((tert-butyldimethylsilyl)oxy)-tetradec-1,9-dien-8-one S13 (1.241 g, 2.173 mmol) was 
added in 25 mL THF and the reaction mixture was stirred at -50 °C for 1h.  The reaction was 
quenched with ice-cold 1M HCl and the layers were immediately separated.  The organic 
layer was washed 2x with ice-cold 1M HCl and 3x with H2O.  The combined aqueous layers 
were back extracted 3x with Et2O.  The combined organic layers were dried over MgSO4, 
filtered and concentrated.  The product was purified by column chromatography (eluting with 
5% EtOAc:hex).  The desired tris-protected product was not recovered; however, the bis-
TBS triol was isolated with the TMS group deprotected (S14 MW = 500.90 gmol-1): 1.061 g, 
2.1182 mmol, 97.5%.  Due to the sensitivity of the product, the monodeprotected product 
was taken on immediately to the next reaction.  1H NMR (300 MHz, CDCl3): δ 5.83-5.69 
 128 
 
(m, 1H), 5.07-5.01 (m, 2H), 4.30-4.28 (m, 1H), 4.02-4.00 (m, 1H), 3.49 (d, J = 2.8 Hz, 1H), 
3.42-3.37 (m, 1H), 2.54-2.51 (m, 2H), 2.48-2.34 (m, 2H), 2.32-2.23 (m, 2H), 1.70-1.60 (m, 
1H), 1.57-1.45 (m, 2H), 1.43-1.23 (m, 4H), 0.87 (s, 9H), 0.86 (s, 9H), 0.83-0.79 (m, 6H), 
0.08 (s, 3H), 0.06 (s, 3H), 0.01 (s, 3H), 0.00 (s, 3H). 
 
Spiroketal 74: Preparation of (2R,4S,6R,8R,9S)-2-allyl-8-ethyl-9-methyl-1,7-
dioxaspiro[5.5]undecan-4-ol 74.  A 25 mL flame dried vial under argon was charged with 
(4R,6S,11S,12R)-4,12-bis((tert-butyldimethylsilyl)oxy)-6-hydroxy-11-methyl-tetradec-1-ene-
8-one S14 (0.923 g, 1.843 mmol) in toluene (9.0 mL) at -78 °C.  HF/pyridine (1 mL) was 
added dropwise and the reaction mixture was stirred at -78 °C.  The reaction was quenched 
with saturated aqueous NaHCO3 and warmed.  The layers were separated and the aqueous 
layer was extracted 2x with Et2O.  The combined organic layers were dried over MgSO4, 
filtered and concentrated.  The product was purified by column chromatography (eluting with 
30% EtOAc:hex) to yield: 0.406 g, 1.5961 mmol, 86.6%.  1H NMR (400 MHz, CDCl3): δ 
5.84 (dddd, J = 6.8, 7.6, 10.4, 17.2 Hz, 1H), 5.10-5.01 (m, 2H), 4.117 (tt, J = 4.8, 4.8, 11.2, 
11.2, 1H), 3.56 (dddd, J = 2.0, 5.2, 7.6, 11.2 Hz, 1H), 3.01 (dt, J = 2.4, 10.0 Hz, 1H), 2.33-
2.26 (m, 1H), 2.21-2.14 (m, 1H), 2.00-1.92 (m, 2H), 1.68-1.59 (m, 2H), 1.55-1.43 (m, 4H), 
1.30-1.20 (m, 3H), 1.13 (q, J = 11.6 Hz, 1H), 0.89 (t, J = 7.2 Hz, 3H), 0.79 (d, J = 6.4 Hz, 
3H); 13C NMR (100 MHz, CDCl3): δ .0, 116.7, 97.2, 75.9, 67.6, 64.8, 44.9, 40.4, 40.2, 35.7, 
34.6, 27.9, 25.8, 17.8, 10.2; IR (film): 3368, 3077, 2956, 2930, 2875, 1643, 1383, 1185, 984, 
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911; MS (ESI): calculated for C15H26O3 [M+Na]+: 277.2, found 277.2; [α] 25D  = +88.86 (c 
0.55, CH2Cl2). 
 
Alkylation Product 75: Preparation of (4S,5R)-3-((R)-2,4-dimethylpent-4-enoyl)-4-
methyl-5-phenyloxazolidin-2-one 75.  A 250 mL flame-dried round bottom flask under argon 
was charged with diisopropyl amine (3.01 mL, 21.950 mmol) in 25 mL THF at -78 °C.  n-
Butyllithium (1.6 M, 16.65 mL, 21.650 mmol) was added and the reaction mixture was 
stirred for 10 min at -78 °C, 10 min at 0 °C, and 10 min at -78 °C.  (4S,5R)-4-methyl-5-
phenyl-3-propionyloxazolidin-2-one 40 (5.000 g, 21.435 mmol) was added in 25 mL THF 
and the reaction mixture was stirred for 30 min at -78 °C.  3-iodo-2-methylprop-1-ene 75 
(7.451 g, 40.941 mmol) was added and the reaction mixture stirred for 1 h at -78 °C, 2 h at -
40 °C, and 15 min at -20 °C.  The reaction was quenched with saturated aqueous NH4Cl.  
The THF was removed under reduced pressure and the aqueous layer was extracted 2x with 
CH2Cl2.  The combined aqueous layers were washed with saturated aqueous NaHCO3, dried 
over MgSO4, filtered and concentrated.  The product was purified by column 
chromatography (eluting with 15% EtOAc:hex) to yield: 3.448 g, 11.998 mmol, 56%.  1H 
NMR (400 MHz, CDCl3): δ 7.41-7.27 (m, 5H), 5.64 (d, J = 7.2 Hz, 1H), 4.80-4.67 (m, 3H), 
4.05-3.96 (m, 1H), 2.50 (dd, J = 6.8, 13.6 Hz, 1H), 2.04 (dd, J = 7.6, 14.0 Hz, 1H), 1.74 (s, 
3H), 1.14 (d, J = 6.8 Hz, 3H), 0.83 (d, J = 6.4 Hz, 3H); 13C NMR (100 MHz, CDCl3): δ 
176.7, 152.7, 142.8, 133.3, 128.7, 128.6, 125.6, 112.3, 78.7, 54.8, 41.6, 35.6, 22.2, 16.7, 
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14.5; IR (film): , 3035, 2979, 2936, 2879, 1782, 1700, 1456, 1343, 1238, 1196, 1122, 958, 
768, 700; MS (ESI): calculated for C17H21NO3 [M+Na]+: 310.1, found 310.1; [α] 23D  = -33.50 
(c 1.15, CH2Cl2). 
 
Primary Alcohol 36: Preparation of (R)-2,4-dimethylpent-4-en-1-ol 36.  A 25 mL 
flame-dried round bottom flask under argon was charged with lithium aluminum hydride 
(0.066 g, 1.740 mmol) in diethyl ether (5.8 mL) at 0 °C.  (4S,5R)-3-((R)-2,4-dimethylpent-4-
enoyl)-4-methyl-5-phenyloxazolidin-2-one 75 (0.500 g, 1.740 mmol) was added in 3 mL 
Et2O and the reaction mixture was stirred for 30 min at rt.  The reaction was quenched with 
0.06 mL H2O, followed by 0.066 mL 15% NaOH and 0.198 mL H2O.  The reaction mixture 
was filtered through Celite and the layers separated.  The aqueous layer was extracted 2x 
with Et2O.  The combined organic layers were dried over MgSO4, filtered and concentrated 
at 0 °C.  The product was purified by column chromatography (eluting with 25-75% 
EtOAc:hex) and taken directly on to the next reaction.  1H NMR (400 MHz, CDCl3): δ 4.70 
(d, J = 21.6 Hz, 2H), 3.50-3.38 (m, 2H), 2.14-2.07 (m, 1H), 1.87-1.78 (m, 2H), 1.69 (s, 3H), 
0.86 (d, J = 6.4 Hz, 3H). 
 
 
 131 
 
 
Protected Primary Alcohol 78 Preparation of (R)-2,4-dimethylpent-4-en-1-yl 
benzoate 78.  A 25 mL flame-dried round bottom flask under argon was charged with 
previously isolated (R)-2,4-dimethylpent-4-en-1-ol 36 in dichloromethane (8.7 mL) at 0 °C.  
Pyridine (0.30 mL, 3.663 mmol) was added followed by benzoyl chloride (0.34 mL, 2.965 
mmol) and the reaction mixture was stirred at 0 °C until complete by TLC.  The reaction was 
quenched with saturated aqueous NaHCO3 and the layers were separated.  The aqueous layer 
was extracted 2x with CH2Cl2.  The combined organic layers were dried over Na2SO4, 
filtered and concentrated at 0 °C.  The product was purified by column chromatography 
(eluting with 5% Et2O:hex) to yield: 0.277 g, 1.2690 mmol, 72.8 %.  1H NMR (400 MHz, 
CDCl3): δ 8.05-8.02 (m, 2H), 7.56-7.52 (m, 1H), 7.45-7.41 (m, 2H), 4.74 (d, J = 26.4, 2H), 
4.21 (dd, J = 5.2, 10.8 Hz, 1H), 4.09 (dd, J = 6.4, 10.8 Hz, 1H), 2.23-2.09 (m, 2H), 1.94 (dd, 
J = 7.6, 13.2 Hz, 1H), 1.72 (s, 3H), 1.00 (d, J = 6.8 Hz); 13C NMR (100 MHz, CDCl3): δ 
166.6, 143.3, 132.8, 130.4, 129.5, 128.3, 112.2, 69.5, 42.2, 30.6, 22.2, 16.9; MS (ESI): 
calculated for C14H18O2 [M+Na]+: 241.1, found 241.1; [α] 25D  = -5.52 (c 0.85, CH2Cl2). 
 
Protected Spiroketal 37: Preparation of (((2R,4S,6R,8R,9S)-2-allyl-8-ethyl-9-
methyl-1,7-dioxaspiro[5.5]undecan-4-yl)oxy)(tert-butyl)dimethylsilane 37.  A 1 dram flame-
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dried vial under argon was charged with (2R,4S,6R,8R,9S)-2-allyl-8-ethyl-9-methyl-1,7-
dioxaspiro[5.5]undecan-4-ol 74 (0.121 g, 0.476 mmol) in dimethyl formamide (2.4 mL) at 0 
°C.  Imidazole (0.071 g, 1.047 mmol) was added followed by tert-butylchlorodimethylsilane 
(0.122 g, 0.809 mmol).  The reaction mixture was allowed to warm overnight while stirring.  
The reaction was quenched with saturated aqueous NaHCO3.  The layers were separated and 
the aqueous layer was extracted 2x with Et2O.  The combined organic layers were dried over 
MgSO4, filtered and concentrated.  The product was purified by column chromatography 
(eluting with 0-2% Et2O:hex) to yield: 0.140 g, 0.3801 mmol, 79.9%.  1H NMR (400 MHz, 
CDCl3): δ 5.85 (dddd, J = 6.4, 7.2, 10.0, 17.2 Hz, 1H), 5.09-5.00 (m, 2H), 4.09 (tt, J = 4.8, 
4.8, 10.8, 10.8 Hz, 1H), 3.55-3.49 (m, 1H), 3.00 (dt, J = 2.8, 9.6, 9.6 Hz, 1H), 2.31-2.23 (m, 
1H), 2.18-2.11 (m, 1H), 1.85 (ddd, J = 2.0, 4.8, 12.4 Hz, 1H), 1.82-1.77 (m, 1H), 1.66-1.57 
(m, 2H), 1.54-1.42 (m, 3H), 1.31-1.24 (m, 3H), 1.21-1.12 (m, 1H), 0.89-0.86 (m, 12H), 0.78 
(d, J = 6.8 Hz, 3H), 0.03 (s, 6H);  13C NMR (100 MHz, CDCl3): δ 135.3, 116.5, 97.2, 75.6, 
67.6, 65.6, 45.3, 41.1, 40.3, 35.7, 34.7, 28.0, 25.9, 18.1, 17.9, 10.2, -4.5, -4.6; IR (film): 
3078, 2957, 2930, 2876, 2858, 1386, 1088, 986, 837, 775; MS (ESI): calculated for 
C21H40O3Si [M+Na]+: 391.3, found 391.3; [α] 25D  = +78.54 (c 0.50, CH2Cl2). 
 
Trisubstituted Olefin 79: Preparation of (R,E)-6-((2R,4S,6R,8R,9S)-4-((tert-
butyldimethylsilyl)oxy)-8-ethyl-9-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)-2,4-
dimethylhex-4-en-1-yl benzoate 79.  A 10 mL, 2 neck, flame dried, round bottom flask under 
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argon fitted with a reflux condenser was charged with (R)-2,4-dimethylpent-4-en-1-yl 
benzoate 78 (0.101 g, 0.461 mmol) in 0.1 mL toluene, and the reaction mixture was heated to 
80 °C.  (((2R,4S,6R,8R,9S)-2-allyl-8-ethyl-9-methyl-1,7-dioxaspiro[5.5]undecan-4-
yl)oxy)(tert-butyl)dimethylsilane 79 (0.034 g, 0.092 mmol) in 0.1 mL toluene and Grubb's 
2nd generation catalyst (0.015 g, 0.018 mmol) in 0.1 mL toluene were added dropwise from 
separate syringes over several hours, and the reaction mixture was stirred at 80 °C overnight.  
Potassium 2-cyanoacetate (0.300 g, 2.66 mmol) in 0.4 mL methanol was added and the 
reaction mixture was stirred at room temperature for 30 min.  The solvent was removed and 
the product was purified by column chromatography (eluting with 2% Et2O:hex) to yield: 
0.023 g, 0.0412 mmol, 44.6 % as a 2:1 mixture of alkene isomers separable by HPLC.  1H 
NMR (400 MHz, CDCl3): δ 8.04-8.02 (m, 2H), 7.55-7.40 (m, 3H), 5.25 (t, J = 7.2 Hz, 1H), 
4.20 (dd, J = 5.2, 10.8 Hz, 1H), 4.12-4.05 (m, 2H), 3.51-3.46 (m, 1H), 3.00 (dt, J = 2.8, 9.6, 
9.6 Hz, 1H), 2.26-2.08 (m, 4H), 1.91-1.78 (m,3H), 1.62-1.60 (m, 4H), 1.53-1.42 (m, 3H), 
1.31-1.22 (m, 3H), 1.20-1.11 (m, 2H), 0.96 (d, J = 6.4 Hz, 3H), 0.89-0.85 (m, 12H), 0.77 (d, 
J = 6.4 Hz, 3H), 0.03 (s, 6H); 13C NMR (125 MHz, CDCl3): δ 166.6, 134.3, 132.8, 130.5, 
129.5, 128.3, 122.9, 97.2, 75.6, 69.6, 68.0, 65.6, 45.3, 44.0, 41.2, 35.7, 34.6, 34.4, 31.6, 30.9, 
28.0, 25.9, 25.9, 22.7, 18.1, 17.9, 16.9, 16.3, 14.1, 10.2, -4.5, -4.6; IR (film): 2957, 2929, 
2875, 2857, 1724, 1453, 1386, 1274, 1111, 1070, 986, 836, 711; MS (ESI): calculated for 
C33H54O5Si [M+Na]+: 581.4, found 581.4; [α] 23D  = +81.79 (c 0.45, CH2Cl2). 
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Primary Alcohol S15: Preparation of (R,E)-6-((2R,4S,6R,8R,9S)-4-((tert-
butyldimethylsilyl)oxy)-8-ethyl-9-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)-2,4-
dimethylhex-4-en-1-ol S15.  A 1 dram flame dried vial under argon was charged with (R,E)-
6-((2R,4S,6R,8R,9S)-4-((tert-butyldimethylsilyl)oxy)-8-ethyl-9-methyl-1,7-
dioxaspiro[5.5]undecan-2-yl)-2,4-dimethylhex-4-en-1-yl benzoate 79 (0.009 g, 0.016 mmol) 
in methanol (0.161 mL) at rt.  Sodium hydroxide (0.001 g, 0.016 mmol) was added and the 
reaction mixture was stirred at rt for 1 h.  The reaction was quenched with saturated aqueous 
NH4Cl.  The layers were separated and the aqueous layer was extracted 2x with EtOAc.  The 
combined organic layers were dried over Na2SO4, filtered and concentrated.  The product 
was purified by column chromatography (eluting with 15% EtOAc:hex) to yield: 0.007 g, 
0.0154 mmol, 95.6%.  1H NMR (400 MHz, CDCl3): δ 5.25 (t, J = 7.6 Hz, 1H), 4.12-4.16 (m, 
2H), 3.43-3.40 (m, 1H), 3.00 (dt, J = 2.4, 9.6, 9.6 Hz, 1H), 2.19-2.15 (m, 2H), 2.10-2.04 (m, 
1H), 1.86-1.77 (m, 4H), 1.87-1.56 (m, 5H), 1.53-1.41 (m, 4H), 1.31-1.13 (m, 6H), 0.91-0.85 
(m, 15H), 0.78 (d, J = 6.8 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (100 MHz, CDCl3): 
δ 135.7, 122.3, 97.3, 75.7, 68.5, 68.0, 65.7, 45.3, 44.6, 41.1, 35.6, 34.6, 34.2, 33.7, 28.0, 25.9, 
18.2, 17.9, 16.8, 16.2, 10.2, -4.5, -4.6; IR (film): 3381 (br), 2956, 2929, 2878, 2858, 1463, 
1386, 1254, 1080, 987, 837, 775; MS (ESI): calculated for C26H50O4Si [M+Na]+: 477.3, 
found 477.3; [α] 23D  = +60.34 (c 0.35, CH2Cl2). 
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Aldehyde 80: Preparation of (R,E)-6-((2R,4S,6R,8R,9S)-4-((tert-
butyldimethylsilyl)oxy)-8-ethyl-9-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)-2,4-
dimethylhex-4-enal 80.  a 1 dram vial was charged with (R,E)-6-((2R,4S,6R,8R,9S)-4-((tert-
butyldimethylsilyl)oxy)-8-ethyl-9-methyl-1,7-dioxaspiro[5.5]undecan-2-yl)-2,4-
dimethylhex-4-en-1-ol S15 (0.005 g, 0.011 mmol) in wet dichloromethane (0.110 mL) at rt.  
Sodium bicarbonate (0.009 g, 0.110 mmol) was added followed by Dess-Martin Periodinane 
(0.009 g, 0.022 mmol) and the reaction mixture was stirred at rt until the reaction was 
complete by TLC.  The reaction was quenched with 5:1 Na2S2O3:NaHCO3.  The layers were 
separated and the aqueous layer was extracted 2x with CH2Cl2.  The combined organic layers 
were dried over Na2SO4, filtered, and concentrated.  The product was purified by column 
chromatography (eluting with 5% EtOAc:hex) to yield: 0.005 g, 0.011 mmol, 100%.  1H 
NMR (500 MHz, CDCl3): δ 9.62 (d, J = 1.6 Hz, 1H), 5.27 (t, J = 5.2 Hz, 1H), 4.08 (m, 1H), 
3.50-3.45 (m, 1H), 2.98 (dt, J = 2.0, 7.6, 7.6 Hz, 1H), 2.52-2.48 (m, 1H), 2.46-2.42 (m, 1H), 
2.23-2.18 (m, 1H), 2.16-2.10 (m, 1H), 1.98 (dd, J = 6.4, 10.8 Hz, 1H), 1.85 (dd, J = 2.4, 10.0 
Hz, 1H), 1.79-1.76 (m, 1H), 1.70-1.61 (m, 4H), 1.52-1.40 (m, 3H), 1.30-1.23 (m, 4H), 1.15 
(q, J = 9.6 Hz, 1H), 1.03 (d, J = 5.6 Hz, 3H), 0.90-0.86 (m, 12H), 0.78 (d, J = 5.2 Hz, 3H), 
0.04 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 205.0, 133.1, 123.8, 97.2, 75.7, 
67.9, 65.6, 45.4, 44.4, 41.2, 40.8, 35.7, 34.6, 34.4, 28.0, 25.9, 25.9, 18.1, 17.9, 16.2, 13.2, 
10.2, -4.5, -4.6; IR (film): 2957, 2930, 2879, 2857, 2708, 1731, 1462, 1386, 1252, 1086, 987, 
 136 
 
836, 777; MS (ESI): calculated for C26H48O4Si [M+Na]+: 475.3, found 475.3; [α] 25D  = +50.46 
(c 0.25, CH2Cl2). 
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